[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"$fIxf1frmgAjN9RSWx1zLjmNWEQ_J1XXdh3GurlVHNR14":3},{"sponsor":4,"sponsorVariants":5,"totalTrials":6,"truncated":7,"activeTrials":8,"phase3Count":9,"totalEnrollment":10,"activePrograms":11,"nonDrugCount":12,"topConditions":13,"upcomingReadouts":35,"phaseBuckets":85,"rows":92},"Northwell Health",[4],460,false,91,17,134058,42,309,[14,17,20,23,25,27,30,32],{"name":15,"count":16},"Schizophrenia",21,{"name":18,"count":19},"Glioblastoma Multiforme",11,{"name":21,"count":22},"Stroke",9,{"name":24,"count":22},"Bipolar Disorder",{"name":26,"count":22},"Glioblastoma",{"name":28,"count":29},"Schizoaffective Disorder",8,{"name":31,"count":29},"Brain Cancer",{"name":33,"count":34},"Anaplastic Astrocytoma",7,[36,41,46,51,56,61,66,71,76,81],{"nctId":37,"briefTitle":38,"date":39,"intervention":40},"NCT04724720","Famotidine vs Placebo for the Treatment of Non-Hospitalized Adults With COVID-19","2021-05-03","Famotidine",{"nctId":42,"briefTitle":43,"date":44,"intervention":45},"NCT03581877","Peripheral Systemic Thrombolysis Versus Catheter Directed Thrombolysis for Submassive PE","2023-03-19","Alteplase",{"nctId":47,"briefTitle":48,"date":49,"intervention":50},"NCT04094298","Use of Extended Release Triamcinolone in the Treatment of Rotator Cuff Disease","2024-10-10","FX006",{"nctId":52,"briefTitle":53,"date":54,"intervention":55},"NCT04486118","Centrally Acting ACE Inhibition in SLE","2025-06-03","Lisinopril Pills",{"nctId":57,"briefTitle":58,"date":59,"intervention":60},"NCT04685772","Assessment of the Efficacy of Medrol Dose Pack for Acute Post-Concussive Headaches","2025-12-01","Methylprednisolone",{"nctId":62,"briefTitle":63,"date":64,"intervention":65},"NCT06379425","Impact of Preoperative Opioid-free Multimodal Analgesia on Time to Trial of Void in Ambulatory Urogynecologic Surgeries","2026-03-01","Acetaminophen",{"nctId":67,"briefTitle":68,"date":69,"intervention":70},"NCT04228172","Genotypic Influences on Network Progression in Parkinson's Disease","2026-04-06","DNA\u002FGeneticTesting",{"nctId":72,"briefTitle":73,"date":74,"intervention":75},"NCT07193862","Pilot Study of an Implantable Microdevice for In Situ Evaluation of Drug Response in Patients With Colorectal Liver Metastasis","2026-04-15","Doxorubicin, FOLFOX, Botensilimab, Balstilimab, Bevacizumab, FOLFIRI, FOLFIRINOX, AGEN2373",{"nctId":77,"briefTitle":78,"date":79,"intervention":80},"NCT03543839","Trial of Belimumab in Early Lupus","2026-08","Belimumab",{"nctId":82,"briefTitle":83,"date":79,"intervention":84},"NCT05289167","Post-Transplant Cyclophosphamide, Bortezomib and Abatacept for the Prevention of Graft-versus-Host-Disease (GvHD)","Cyclophosphamide",[86,87,88,89,90,91],"EARLY_PHASE1","PHASE1","PHASE2","PHASE3","PHASE4","NA",[93,226,277,316,348,374,392,416,434,463,493,511,537,580,602,642,686,713,731,753,771,797,829,847,873,891,909,927,945,974,992,1016,1041,1059,1093,1124,1148,1172,1192,1216,1240,1263,1285,1327,1361,1405,1427,1452,1480,1498,1516,1534,1552,1580,1598,1623,1649,1672,1697,1715,1733,1751,1778,1803,1821,1848,1866,1892,1910,1934,1961,1979,2005,2027,2045,2069,2093,2118,2136,2154,2182,2200,2218,2236,2263,2281,2308,2333,2351,2377,2400,2427,2445,2463,2481,2499,2517,2559,2584,2602,2624,2647,2670,2697,2725,2752,2775,2802,2827,2845,2873,2897,2921,2950,2968,2986,3004,3022,3040,3058,3082,3100,3125,3148,3174,3201,3219,3241,3266,3288,3314,3342,3367,3394,3417,3440,3462,3487,3513,3538,3556,3579,3602,3627,3649,3674,3697,3720,3744,3771,3797,3822,3846,3870,3903,3926,3949,3972,3995,4020,4042,4064,4088,4106,4128,4155,4178,4196,4220,4243,4267,4290,4316,4334,4358,4382,4404,4428,4451,4476,4501,4526],{"intervention":94,"totalTrials":95,"cells":96},"Risperidone",10,{"EARLY_PHASE1":97,"PHASE1":100,"PHASE2":102,"PHASE3":104,"PHASE4":106,"NA":181},{"trials":98,"activeCount":99},[],0,{"trials":101,"activeCount":99},[],{"trials":103,"activeCount":99},[],{"trials":105,"activeCount":99},[],{"trials":107,"activeCount":180,"soonestReadout":160},[108,124,133,145,155,169],{"nctId":109,"briefTitle":110,"status":111,"phases":112,"primaryCompletion":113,"completion":113,"start":114,"enrollment":115,"conditions":116,"interventions":117},"NCT00048802","Treatment and Outcome of Early Onset Bipolar Disorder","COMPLETED",[90],"2006-08","2002-08",40,[24],[118,119,120,94,121,122,123],"Lithium","Olanzapine","Divalproex","Quetiapine","Ziprasidone","Aripriprazole",{"nctId":125,"briefTitle":126,"status":111,"phases":127,"primaryCompletion":128,"completion":128,"start":129,"enrollment":130,"conditions":131,"interventions":132},"NCT00000374","Treatment for First-Episode Schizophrenia",[90],"2007-05","1998-09",125,[15],[119,94],{"nctId":134,"briefTitle":135,"status":111,"phases":136,"primaryCompletion":137,"completion":137,"start":138,"enrollment":139,"conditions":140,"interventions":141},"NCT00330863","Preventing Relapse in Schizophrenia: Oral Antipsychotics Compared To Injectables: Evaluating Efficacy",[90],"2011-01","2006-05",357,[15,28],[142,94,119,121,122,143,144],"Risperidone microspheres","Aripiprazole","Paliperidone",{"nctId":146,"briefTitle":147,"status":111,"phases":148,"primaryCompletion":149,"completion":150,"start":151,"enrollment":152,"conditions":153,"interventions":154},"NCT00320671","Comparison of Aripiprazole and Risperidone for the Treatment of People With First-Episode Psychosis",[90],"2014-12","2015-12","2005-12",198,[15],[143,94],{"nctId":156,"briefTitle":157,"status":158,"phases":159,"primaryCompletion":160,"completion":161,"start":162,"enrollment":163,"conditions":164,"interventions":166},"NCT07483294","Cerebellum-based Imaging Neural Markers for Antipsychotic Response","RECRUITING",[90],"2029-12-01","2030-06-01","2025-11-01",120,[165],"Psychosis; Acute",[167,168],"risperidone","aripiprazole",{"nctId":170,"briefTitle":171,"status":158,"phases":172,"primaryCompletion":173,"completion":173,"start":174,"enrollment":175,"conditions":176,"interventions":178},"NCT06969755","Biomarkers to Enhance Early Schizophrenia Treatment",[90],"2030-07-30","2025-09-30",180,[177],"Schizophenia Disorder",[168,167,179],"clozapine",2,{"trials":182,"activeCount":99},[183,194,205,216],{"nctId":184,"briefTitle":185,"status":111,"phases":186,"completion":187,"start":188,"enrollment":29,"conditions":189,"interventions":192},"NCT00169988","Antidepressant and Antipsychotic to Treat Attenuated Positive and Negative Symptoms",[91],"2007-04","2004-03",[190,191],"Prodromal Schizophrenia","Psychotic Disorders",[167,193],"sertraline-primary",{"nctId":195,"briefTitle":196,"status":111,"phases":197,"primaryCompletion":198,"completion":198,"start":199,"enrollment":200,"conditions":201,"interventions":204},"NCT01878513","Prospective Cytochrome P450 Genotyping and Clinical Outcomes in Patients With Psychosis",[91],"2018-07-31","2009-09-23",88,[15,28,202,203],"Psychotic Disorder Not Otherwise Specified","Severe Bipolar Disorder With Psychotic Features",[167],{"nctId":206,"briefTitle":207,"status":208,"phases":209,"primaryCompletion":210,"completion":210,"start":211,"enrollment":99,"conditions":212,"interventions":215},"NCT02661347","Transcranial Direct Current Stimulation for Hallucinations in First-Episode Schizophrenia","WITHDRAWN",[91],"2016-12-01","2016-02",[15,213,28,214],"Schizophreniform","Psychosis Not Otherwise Specified (NOS)",[94],{"nctId":217,"briefTitle":218,"status":111,"phases":219,"primaryCompletion":220,"completion":220,"start":221,"enrollment":19,"conditions":222,"interventions":225},"NCT01931059","Acute D2 Receptor Blockade Induced Neuronal Network Changes in Human Volunteers",[91],"2016-07","2013-07",[223,224],"Imaging of the Brain and Antipsychotics","Neuronal Network Changes",[94],{"intervention":143,"totalTrials":227,"cells":228},6,{"EARLY_PHASE1":229,"PHASE1":231,"PHASE2":233,"PHASE3":235,"PHASE4":237,"NA":266},{"trials":230,"activeCount":99},[],{"trials":232,"activeCount":99},[],{"trials":234,"activeCount":99},[],{"trials":236,"activeCount":99},[],{"trials":238,"activeCount":180,"soonestReadout":160},[239,243,247,251,255],{"nctId":134,"briefTitle":135,"status":111,"phases":240,"primaryCompletion":137,"completion":137,"start":138,"enrollment":139,"conditions":241,"interventions":242},[90],[15,28],[142,94,119,121,122,143,144],{"nctId":146,"briefTitle":147,"status":111,"phases":244,"primaryCompletion":149,"completion":150,"start":151,"enrollment":152,"conditions":245,"interventions":246},[90],[15],[143,94],{"nctId":156,"briefTitle":157,"status":158,"phases":248,"primaryCompletion":160,"completion":161,"start":162,"enrollment":163,"conditions":249,"interventions":250},[90],[165],[167,168],{"nctId":170,"briefTitle":171,"status":158,"phases":252,"primaryCompletion":173,"completion":173,"start":174,"enrollment":175,"conditions":253,"interventions":254},[90],[177],[168,167,179],{"nctId":256,"briefTitle":257,"status":258,"phases":259,"primaryCompletion":260,"completion":260,"start":261,"enrollment":22,"conditions":262,"interventions":264},"NCT02357849","Fluoxetine vs Aripiprazole Comparative Trial (FACT)","TERMINATED",[90],"2022-04-04","2014-07",[263],"Attenuated Psychosis Syndrome",[143,265],"Fluoxetine",{"trials":267,"activeCount":99},[268],{"nctId":269,"briefTitle":270,"status":258,"phases":271,"completion":138,"start":272,"enrollment":273,"conditions":274,"interventions":276},"NCT00169949","Aripiprazole Treatment of the Prodrome",[91],"2004-01",30,[190,275],"Prodromal Psychosis",[168],{"intervention":278,"totalTrials":279,"cells":280},"Clozapine",3,{"EARLY_PHASE1":281,"PHASE1":283,"PHASE2":285,"PHASE3":296,"PHASE4":298,"NA":314},{"trials":282,"activeCount":99},[],{"trials":284,"activeCount":99},[],{"trials":286,"activeCount":99},[287],{"nctId":288,"briefTitle":289,"status":111,"phases":290,"primaryCompletion":291,"completion":291,"start":292,"enrollment":293,"conditions":294,"interventions":295},"NCT00042224","Electroconvulsive Therapy in Clozapine Refractory Schizophrenia",[87,88],"2008-07","2000-12",39,[15],[278],{"trials":297,"activeCount":99},[],{"trials":299,"activeCount":313,"soonestReadout":173},[300,309],{"nctId":301,"briefTitle":302,"status":111,"phases":303,"primaryCompletion":304,"completion":304,"start":305,"enrollment":306,"conditions":307,"interventions":308},"NCT00048828","Treating Drug-Resistant Childhood Schizophrenia",[90],"2006-06","2001-10",41,[15],[119,278],{"nctId":170,"briefTitle":171,"status":158,"phases":310,"primaryCompletion":173,"completion":173,"start":174,"enrollment":175,"conditions":311,"interventions":312},[90],[177],[168,167,179],1,{"trials":315,"activeCount":99},[],{"intervention":80,"totalTrials":180,"cells":317},{"EARLY_PHASE1":318,"PHASE1":320,"PHASE2":322,"PHASE3":324,"PHASE4":335,"NA":346},{"trials":319,"activeCount":99},[],{"trials":321,"activeCount":99},[],{"trials":323,"activeCount":99},[],{"trials":325,"activeCount":99},[326],{"nctId":327,"briefTitle":328,"status":111,"phases":329,"primaryCompletion":330,"completion":330,"start":331,"enrollment":9,"conditions":332,"interventions":334},"NCT02347891","Belimumab in Idiopathic Inflammatory Myositis",[88,89],"2020-11","2015-01",[333],"Myositis",[80],{"trials":336,"activeCount":313,"soonestReadout":79},[337],{"nctId":77,"briefTitle":78,"status":158,"phases":338,"primaryCompletion":79,"completion":339,"start":340,"enrollment":273,"conditions":341,"interventions":344},[90],"2026-12","2020-09-15",[342,343],"Lupus Erythematosus, Systemic","Lupus Erythematosus",[80,345],"Belimumab\u002FPlacebo",{"trials":347,"activeCount":99},[],{"intervention":45,"totalTrials":313,"cells":349},{"EARLY_PHASE1":350,"PHASE1":352,"PHASE2":354,"PHASE3":356,"PHASE4":358,"NA":372},{"trials":351,"activeCount":99},[],{"trials":353,"activeCount":99},[],{"trials":355,"activeCount":99},[],{"trials":357,"activeCount":99},[],{"trials":359,"activeCount":313,"soonestReadout":44},[360],{"nctId":42,"briefTitle":43,"status":361,"phases":362,"primaryCompletion":44,"completion":363,"start":364,"enrollment":365,"conditions":366,"interventions":371},"ACTIVE_NOT_RECRUITING",[90],"2025-03-19","2019-01-28",31,[367,368,369,370],"Pulmonary Embolism","Pulmonary Hypertension","Thromboembolism","Right Ventricular Dysfunction",[45],{"trials":373,"activeCount":99},[],{"intervention":345,"totalTrials":313,"cells":375},{"EARLY_PHASE1":376,"PHASE1":378,"PHASE2":380,"PHASE3":382,"PHASE4":384,"NA":390},{"trials":377,"activeCount":99},[],{"trials":379,"activeCount":99},[],{"trials":381,"activeCount":99},[],{"trials":383,"activeCount":99},[],{"trials":385,"activeCount":313,"soonestReadout":79},[386],{"nctId":77,"briefTitle":78,"status":158,"phases":387,"primaryCompletion":79,"completion":339,"start":340,"enrollment":273,"conditions":388,"interventions":389},[90],[342,343],[80,345],{"trials":391,"activeCount":99},[],{"intervention":393,"totalTrials":313,"cells":394},"Celecoxib",{"EARLY_PHASE1":395,"PHASE1":397,"PHASE2":399,"PHASE3":401,"PHASE4":403,"NA":414},{"trials":396,"activeCount":99},[],{"trials":398,"activeCount":99},[],{"trials":400,"activeCount":99},[],{"trials":402,"activeCount":99},[],{"trials":404,"activeCount":313,"soonestReadout":64},[405],{"nctId":62,"briefTitle":63,"status":158,"phases":406,"primaryCompletion":64,"completion":64,"start":407,"enrollment":408,"conditions":409,"interventions":412},[90],"2024-03-01",70,[410,411],"Pain, Postoperative","Postoperative Pain, Acute",[65,393,413],"Gabapentin",{"trials":415,"activeCount":99},[],{"intervention":413,"totalTrials":313,"cells":417},{"EARLY_PHASE1":418,"PHASE1":420,"PHASE2":422,"PHASE3":424,"PHASE4":426,"NA":432},{"trials":419,"activeCount":99},[],{"trials":421,"activeCount":99},[],{"trials":423,"activeCount":99},[],{"trials":425,"activeCount":99},[],{"trials":427,"activeCount":313,"soonestReadout":64},[428],{"nctId":62,"briefTitle":63,"status":158,"phases":429,"primaryCompletion":64,"completion":64,"start":407,"enrollment":408,"conditions":430,"interventions":431},[90],[410,411],[65,393,413],{"trials":433,"activeCount":99},[],{"intervention":435,"totalTrials":180,"cells":436},"acetaminophen",{"EARLY_PHASE1":437,"PHASE1":439,"PHASE2":441,"PHASE3":443,"PHASE4":445,"NA":451},{"trials":438,"activeCount":99},[],{"trials":440,"activeCount":99},[],{"trials":442,"activeCount":99},[],{"trials":444,"activeCount":99},[],{"trials":446,"activeCount":313,"soonestReadout":64},[447],{"nctId":62,"briefTitle":63,"status":158,"phases":448,"primaryCompletion":64,"completion":64,"start":407,"enrollment":408,"conditions":449,"interventions":450},[90],[410,411],[65,393,413],{"trials":452,"activeCount":99},[453],{"nctId":454,"briefTitle":455,"status":258,"phases":456,"primaryCompletion":457,"completion":457,"start":458,"enrollment":11,"conditions":459,"interventions":462},"NCT04662567","Oral Versus Intravenous Acetaminophen for Postoperative Pain Control",[91],"2021-09-05","2021-03-12",[460,461],"Postoperative Pain","IVF",[435],{"intervention":464,"totalTrials":313,"cells":465},"Repeated Superselective Intraarterial Cerebral infusion (SIACI) of Bevacizumab (Avastin) with Temozolomide and Radiation",{"EARLY_PHASE1":466,"PHASE1":468,"PHASE2":470,"PHASE3":472,"PHASE4":489,"NA":491},{"trials":467,"activeCount":99},[],{"trials":469,"activeCount":99},[],{"trials":471,"activeCount":99},[],{"trials":473,"activeCount":313,"soonestReadout":478},[474],{"nctId":475,"briefTitle":476,"status":158,"phases":477,"primaryCompletion":478,"completion":479,"start":480,"enrollment":481,"conditions":482,"interventions":487},"NCT05271240","Repeated Superselective Intraarterial Cerebral Infusion (SIACI) of Bevacizumab With Temozolomide and Radiation Compared to Temozolomide and Radiation Alone in Newly Diagnosed GBM",[89],"2027-04-01","2028-04-01","2022-04-27",432,[26,18,483,484,31,485,486],"Glioma, Malignant","GBM","Glioblastoma, IDH-wildtype","Glioblastoma Multiforme, Adult",[464,488],"Temozolomide and Radiation Alone",{"trials":490,"activeCount":99},[],{"trials":492,"activeCount":99},[],{"intervention":488,"totalTrials":313,"cells":494},{"EARLY_PHASE1":495,"PHASE1":497,"PHASE2":499,"PHASE3":501,"PHASE4":507,"NA":509},{"trials":496,"activeCount":99},[],{"trials":498,"activeCount":99},[],{"trials":500,"activeCount":99},[],{"trials":502,"activeCount":313,"soonestReadout":478},[503],{"nctId":475,"briefTitle":476,"status":158,"phases":504,"primaryCompletion":478,"completion":479,"start":480,"enrollment":481,"conditions":505,"interventions":506},[89],[26,18,483,484,31,485,486],[464,488],{"trials":508,"activeCount":99},[],{"trials":510,"activeCount":99},[],{"intervention":50,"totalTrials":313,"cells":512},{"EARLY_PHASE1":513,"PHASE1":515,"PHASE2":517,"PHASE3":519,"PHASE4":533,"NA":535},{"trials":514,"activeCount":99},[],{"trials":516,"activeCount":99},[],{"trials":518,"activeCount":99},[],{"trials":520,"activeCount":313,"soonestReadout":49},[521],{"nctId":47,"briefTitle":48,"status":361,"phases":522,"primaryCompletion":49,"completion":523,"start":524,"enrollment":525,"conditions":526,"interventions":532},[89],"2025-01-31","2019-07-15",65,[527,528,529,530,531],"Rotator Cuff Tears","Rotator Cuff Tendinitis","Rotator Cuff Impingement","Injections","Glucocorticoids",[50],{"trials":534,"activeCount":99},[],{"trials":536,"activeCount":99},[],{"intervention":538,"totalTrials":180,"cells":539},"Intra-arterial Cetuximab",{"EARLY_PHASE1":540,"PHASE1":542,"PHASE2":544,"PHASE3":574,"PHASE4":576,"NA":578},{"trials":541,"activeCount":99},[],{"trials":543,"activeCount":99},[],{"trials":545,"activeCount":180,"soonestReadout":567},[546,563],{"nctId":547,"briefTitle":548,"status":158,"phases":549,"primaryCompletion":550,"completion":551,"start":552,"enrollment":553,"conditions":554,"interventions":561},"NCT02800486","Super Selective Intra-arterial Repeated Infusion of Cetuximab (Erbitux) With Reirradiation for Treatment of Relapsed\u002FRefractory GBM, AA, and AOA",[88],"2035-05","2036-05","2016-05",37,[26,33,555,556,557,31,558,559,560],"Anaplastic Oligoastrocytoma","Glioma","Brain Neoplasm","Brain Tumor","Brain Tumor, Recurrent","Brain Neoplasm, Malignant",[538,562],"Intra-arterial Mannitol",{"nctId":564,"briefTitle":565,"status":158,"phases":566,"primaryCompletion":567,"completion":568,"start":569,"enrollment":570,"conditions":571,"interventions":573},"NCT02861898","Super-selective Intra-arterial Repeated Infusion of Cetuximab for the Treatment of Newly Diagnosed Glioblastoma",[87,88],"2028-12","2029-12","2016-06",33,[26,31,557,558,560,572,484],"EGFR Gene Overexpression",[538,562],{"trials":575,"activeCount":99},[],{"trials":577,"activeCount":99},[],{"trials":579,"activeCount":99},[],{"intervention":562,"totalTrials":180,"cells":581},{"EARLY_PHASE1":582,"PHASE1":584,"PHASE2":586,"PHASE3":596,"PHASE4":598,"NA":600},{"trials":583,"activeCount":99},[],{"trials":585,"activeCount":99},[],{"trials":587,"activeCount":180,"soonestReadout":567},[588,592],{"nctId":547,"briefTitle":548,"status":158,"phases":589,"primaryCompletion":550,"completion":551,"start":552,"enrollment":553,"conditions":590,"interventions":591},[88],[26,33,555,556,557,31,558,559,560],[538,562],{"nctId":564,"briefTitle":565,"status":158,"phases":593,"primaryCompletion":567,"completion":568,"start":569,"enrollment":570,"conditions":594,"interventions":595},[87,88],[26,31,557,558,560,572,484],[538,562],{"trials":597,"activeCount":99},[],{"trials":599,"activeCount":99},[],{"trials":601,"activeCount":99},[],{"intervention":84,"totalTrials":180,"cells":603},{"EARLY_PHASE1":604,"PHASE1":606,"PHASE2":608,"PHASE3":620,"PHASE4":638,"NA":640},{"trials":605,"activeCount":99},[],{"trials":607,"activeCount":99},[],{"trials":609,"activeCount":313,"soonestReadout":79},[610],{"nctId":82,"briefTitle":83,"status":158,"phases":611,"primaryCompletion":79,"completion":612,"start":613,"enrollment":614,"conditions":615,"interventions":617},[87,88],"2028-08","2022-03-13",74,[616],"Graft-versus-host Disease",[84,618,619],"Abatacept","Bortezomib",{"trials":621,"activeCount":99},[622],{"nctId":623,"briefTitle":624,"status":111,"phases":625,"primaryCompletion":626,"completion":627,"start":149,"enrollment":95,"conditions":628,"interventions":635},"NCT02566395","Stem Cell Transplantation From HLA Partially-Matched Related Donors for Patients With Hematologic Malignancies",[89],"2022-01-14","2022-02-14",[629,630,631,632,633,634],"Acute Lymphoblastic Leukemia","Acute Myelogenous Leukemia","Myelodysplastic Syndrome","Chronic Myelogenous Leukemia","Non-Hodgkin Lymphoma","Hodgkin Lymphoma",[84,636,637],"Donor Lymphocyte","Haploidentical Stem Cell Transplantation",{"trials":639,"activeCount":99},[],{"trials":641,"activeCount":99},[],{"intervention":643,"totalTrials":279,"cells":644},"Bevacizumab",{"EARLY_PHASE1":645,"PHASE1":647,"PHASE2":659,"PHASE3":680,"PHASE4":682,"NA":684},{"trials":646,"activeCount":99},[],{"trials":648,"activeCount":99},[649],{"nctId":650,"briefTitle":651,"status":652,"phases":653,"primaryCompletion":654,"completion":654,"start":655,"enrollment":273,"conditions":656,"interventions":658},"NCT01083966","Super-Selective Intraarterial Cerebral Infusion of Bevacizumab (Avastin) for Treatment of Vestibular Schwannoma","SUSPENDED",[87],"2027-01","2011-08",[657],"Vestibular Schwannoma",[643],{"trials":660,"activeCount":313,"soonestReadout":674},[661,670],{"nctId":662,"briefTitle":663,"status":111,"phases":664,"primaryCompletion":665,"completion":666,"start":667,"enrollment":365,"conditions":668,"interventions":669},"NCT01811498","Repeated Super-Selective Intraarterial Cerebral Infusion of Bevacizumab (Avastin) for Treatment of Newly Diagnosed GBM",[87,88],"2021-08","2021-10","2013-02",[18,558],[643],{"nctId":671,"briefTitle":672,"status":158,"phases":673,"primaryCompletion":674,"completion":675,"start":676,"enrollment":677,"conditions":678,"interventions":679},"NCT01269853","Repeated Super-selective Intraarterial Cerebral Infusion of Bevacizumab (Avastin) for Treatment of Relapsed GBM and AA",[87,88],"2028-10","2029-10","2010-10",54,[18,33],[643,643],{"trials":681,"activeCount":99},[],{"trials":683,"activeCount":99},[],{"trials":685,"activeCount":99},[],{"intervention":687,"totalTrials":313,"cells":688},"Ergocalciferol 50,000 IU",{"EARLY_PHASE1":689,"PHASE1":691,"PHASE2":693,"PHASE3":707,"PHASE4":709,"NA":711},{"trials":690,"activeCount":99},[],{"trials":692,"activeCount":99},[],{"trials":694,"activeCount":313,"soonestReadout":699},[695],{"nctId":696,"briefTitle":697,"status":158,"phases":698,"primaryCompletion":699,"completion":699,"start":700,"enrollment":273,"conditions":701,"interventions":705},"NCT07369063","Impact of Vitamin D Therapy on Thyroid Function and Antibody Levels in Pediatric Graves' Disease",[88],"2027-02-28","2025-08-01",[702,703,704],"Graves Disease","Graves' Disease","Hyperthyroidism",[687,706],"Methimazole",{"trials":708,"activeCount":99},[],{"trials":710,"activeCount":99},[],{"trials":712,"activeCount":99},[],{"intervention":706,"totalTrials":313,"cells":714},{"EARLY_PHASE1":715,"PHASE1":717,"PHASE2":719,"PHASE3":725,"PHASE4":727,"NA":729},{"trials":716,"activeCount":99},[],{"trials":718,"activeCount":99},[],{"trials":720,"activeCount":313,"soonestReadout":699},[721],{"nctId":696,"briefTitle":697,"status":158,"phases":722,"primaryCompletion":699,"completion":699,"start":700,"enrollment":273,"conditions":723,"interventions":724},[88],[702,703,704],[687,706],{"trials":726,"activeCount":99},[],{"trials":728,"activeCount":99},[],{"trials":730,"activeCount":99},[],{"intervention":55,"totalTrials":313,"cells":732},{"EARLY_PHASE1":733,"PHASE1":735,"PHASE2":737,"PHASE3":747,"PHASE4":749,"NA":751},{"trials":734,"activeCount":99},[],{"trials":736,"activeCount":99},[],{"trials":738,"activeCount":313,"soonestReadout":54},[739],{"nctId":52,"briefTitle":53,"status":361,"phases":740,"primaryCompletion":54,"completion":64,"start":741,"enrollment":742,"conditions":743,"interventions":745},[88],"2021-10-01",36,[744],"Systemic Lupus Erythematosus",[55,746],"Benazepril Pill",{"trials":748,"activeCount":99},[],{"trials":750,"activeCount":99},[],{"trials":752,"activeCount":99},[],{"intervention":746,"totalTrials":313,"cells":754},{"EARLY_PHASE1":755,"PHASE1":757,"PHASE2":759,"PHASE3":765,"PHASE4":767,"NA":769},{"trials":756,"activeCount":99},[],{"trials":758,"activeCount":99},[],{"trials":760,"activeCount":313,"soonestReadout":54},[761],{"nctId":52,"briefTitle":53,"status":361,"phases":762,"primaryCompletion":54,"completion":64,"start":741,"enrollment":742,"conditions":763,"interventions":764},[88],[744],[55,746],{"trials":766,"activeCount":99},[],{"trials":768,"activeCount":99},[],{"trials":770,"activeCount":99},[],{"intervention":772,"totalTrials":313,"cells":773},"Anakinra 100Mg\u002F0.67Ml Inj Syringe",{"EARLY_PHASE1":774,"PHASE1":776,"PHASE2":778,"PHASE3":791,"PHASE4":793,"NA":795},{"trials":775,"activeCount":99},[],{"trials":777,"activeCount":99},[],{"trials":779,"activeCount":313,"soonestReadout":784},[780],{"nctId":781,"briefTitle":782,"status":158,"phases":783,"primaryCompletion":784,"completion":784,"start":785,"enrollment":786,"conditions":787,"interventions":790},"NCT03587701","Effects of Anakinra in Subjects With Corticosteroid-resistant\u002FIntolerant Meniere's Disease and Autoimmune Inner Ear Disease",[88],"2026-12-31","2019-01-03",57,[788,789],"Autoimmune Inner Ear Disease","Meniere's Disease",[772,772],{"trials":792,"activeCount":99},[],{"trials":794,"activeCount":99},[],{"trials":796,"activeCount":99},[],{"intervention":798,"totalTrials":313,"cells":799},"Capecitabine",{"EARLY_PHASE1":800,"PHASE1":802,"PHASE2":804,"PHASE3":823,"PHASE4":825,"NA":827},{"trials":801,"activeCount":99},[],{"trials":803,"activeCount":99},[],{"trials":805,"activeCount":313,"soonestReadout":810},[806],{"nctId":807,"briefTitle":808,"status":158,"phases":809,"primaryCompletion":810,"completion":811,"start":812,"enrollment":813,"conditions":814,"interventions":821},"NCT03213002","Oral Capecitabine and Temozolomide (CAPTEM) for Newly Diagnosed GBM",[87,88],"2028-06","2029-06","2017-06-13",67,[815,26,816,817,558,818,819,820,31],"Glioblastoma Multiforme (GBM)","Glioma of Brain","Glioblastoma, Adult","Brain Tumor, Primary","Brain Tumor Adult","Cancer",[798,822],"Temozolomide",{"trials":824,"activeCount":99},[],{"trials":826,"activeCount":99},[],{"trials":828,"activeCount":99},[],{"intervention":822,"totalTrials":313,"cells":830},{"EARLY_PHASE1":831,"PHASE1":833,"PHASE2":835,"PHASE3":841,"PHASE4":843,"NA":845},{"trials":832,"activeCount":99},[],{"trials":834,"activeCount":99},[],{"trials":836,"activeCount":313,"soonestReadout":810},[837],{"nctId":807,"briefTitle":808,"status":158,"phases":838,"primaryCompletion":810,"completion":811,"start":812,"enrollment":813,"conditions":839,"interventions":840},[87,88],[815,26,816,817,558,818,819,820,31],[798,822],{"trials":842,"activeCount":99},[],{"trials":844,"activeCount":99},[],{"trials":846,"activeCount":99},[],{"intervention":848,"totalTrials":313,"cells":849},"Azacitidine",{"EARLY_PHASE1":850,"PHASE1":852,"PHASE2":854,"PHASE3":867,"PHASE4":869,"NA":871},{"trials":851,"activeCount":99},[],{"trials":853,"activeCount":99},[],{"trials":855,"activeCount":313,"soonestReadout":860},[856],{"nctId":857,"briefTitle":858,"status":158,"phases":859,"primaryCompletion":860,"completion":674,"start":861,"enrollment":306,"conditions":862,"interventions":864},"NCT07163793","Pilot Study of Reduced Venetoclax Exposure",[88],"2026-10","2024-10-07",[863],"Acute Myeloid Leukemia in Remission",[848,865,866],"Decitabine","Venetoclax",{"trials":868,"activeCount":99},[],{"trials":870,"activeCount":99},[],{"trials":872,"activeCount":99},[],{"intervention":865,"totalTrials":313,"cells":874},{"EARLY_PHASE1":875,"PHASE1":877,"PHASE2":879,"PHASE3":885,"PHASE4":887,"NA":889},{"trials":876,"activeCount":99},[],{"trials":878,"activeCount":99},[],{"trials":880,"activeCount":313,"soonestReadout":860},[881],{"nctId":857,"briefTitle":858,"status":158,"phases":882,"primaryCompletion":860,"completion":674,"start":861,"enrollment":306,"conditions":883,"interventions":884},[88],[863],[848,865,866],{"trials":886,"activeCount":99},[],{"trials":888,"activeCount":99},[],{"trials":890,"activeCount":99},[],{"intervention":866,"totalTrials":313,"cells":892},{"EARLY_PHASE1":893,"PHASE1":895,"PHASE2":897,"PHASE3":903,"PHASE4":905,"NA":907},{"trials":894,"activeCount":99},[],{"trials":896,"activeCount":99},[],{"trials":898,"activeCount":313,"soonestReadout":860},[899],{"nctId":857,"briefTitle":858,"status":158,"phases":900,"primaryCompletion":860,"completion":674,"start":861,"enrollment":306,"conditions":901,"interventions":902},[88],[863],[848,865,866],{"trials":904,"activeCount":99},[],{"trials":906,"activeCount":99},[],{"trials":908,"activeCount":99},[],{"intervention":618,"totalTrials":313,"cells":910},{"EARLY_PHASE1":911,"PHASE1":913,"PHASE2":915,"PHASE3":921,"PHASE4":923,"NA":925},{"trials":912,"activeCount":99},[],{"trials":914,"activeCount":99},[],{"trials":916,"activeCount":313,"soonestReadout":79},[917],{"nctId":82,"briefTitle":83,"status":158,"phases":918,"primaryCompletion":79,"completion":612,"start":613,"enrollment":614,"conditions":919,"interventions":920},[87,88],[616],[84,618,619],{"trials":922,"activeCount":99},[],{"trials":924,"activeCount":99},[],{"trials":926,"activeCount":99},[],{"intervention":619,"totalTrials":313,"cells":928},{"EARLY_PHASE1":929,"PHASE1":931,"PHASE2":933,"PHASE3":939,"PHASE4":941,"NA":943},{"trials":930,"activeCount":99},[],{"trials":932,"activeCount":99},[],{"trials":934,"activeCount":313,"soonestReadout":79},[935],{"nctId":82,"briefTitle":83,"status":158,"phases":936,"primaryCompletion":79,"completion":612,"start":613,"enrollment":614,"conditions":937,"interventions":938},[87,88],[616],[84,618,619],{"trials":940,"activeCount":99},[],{"trials":942,"activeCount":99},[],{"trials":944,"activeCount":99},[],{"intervention":946,"totalTrials":313,"cells":947},"FEIBA",{"EARLY_PHASE1":948,"PHASE1":950,"PHASE2":952,"PHASE3":968,"PHASE4":970,"NA":972},{"trials":949,"activeCount":99},[],{"trials":951,"activeCount":99},[],{"trials":953,"activeCount":313,"soonestReadout":958},[954],{"nctId":955,"briefTitle":956,"status":158,"phases":957,"primaryCompletion":958,"completion":959,"start":960,"enrollment":961,"conditions":962,"interventions":966},"NCT07032792","Factor VIII Inhibitor Bypass Activity (FEIBA) Versus Fresh Frozen Plasma As First Line Therapy For Bleeding After Cardiac Surgery",[88],"2028-11","2029-11","2025-11-03",140,[963,964,965],"Cardiac Disease","Surgery","Bleeding",[946,967],"FFP",{"trials":969,"activeCount":99},[],{"trials":971,"activeCount":99},[],{"trials":973,"activeCount":99},[],{"intervention":967,"totalTrials":313,"cells":975},{"EARLY_PHASE1":976,"PHASE1":978,"PHASE2":980,"PHASE3":986,"PHASE4":988,"NA":990},{"trials":977,"activeCount":99},[],{"trials":979,"activeCount":99},[],{"trials":981,"activeCount":313,"soonestReadout":958},[982],{"nctId":955,"briefTitle":956,"status":158,"phases":983,"primaryCompletion":958,"completion":959,"start":960,"enrollment":961,"conditions":984,"interventions":985},[88],[963,964,965],[946,967],{"trials":987,"activeCount":99},[],{"trials":989,"activeCount":99},[],{"trials":991,"activeCount":99},[],{"intervention":993,"totalTrials":313,"cells":994},"Cyclophosphamide, Bortezomib, Abatacept",{"EARLY_PHASE1":995,"PHASE1":997,"PHASE2":999,"PHASE3":1010,"PHASE4":1012,"NA":1014},{"trials":996,"activeCount":99},[],{"trials":998,"activeCount":99},[],{"trials":1000,"activeCount":313,"soonestReadout":1005},[1001],{"nctId":1002,"briefTitle":1003,"status":158,"phases":1004,"primaryCompletion":1005,"completion":1005,"start":1006,"enrollment":95,"conditions":1007,"interventions":1009},"NCT06681922","A Phase I-II Study of High-Dose Post-Transplant Cyclophosphamide, Bortezomib, and Abatacept for the Prevention of Graft-Versus-Host Disease (GVHD) Following Allogeneic Hematopoietic Stem Cell Transplantation (HSCT)",[87,88],"2027-10","2024-09-23",[1008],"Graft Vs Host Disease",[993],{"trials":1011,"activeCount":99},[],{"trials":1013,"activeCount":99},[],{"trials":1015,"activeCount":99},[],{"intervention":1017,"totalTrials":313,"cells":1018},"NALIRIFOX",{"EARLY_PHASE1":1019,"PHASE1":1021,"PHASE2":1023,"PHASE3":1035,"PHASE4":1037,"NA":1039},{"trials":1020,"activeCount":99},[],{"trials":1022,"activeCount":99},[],{"trials":1024,"activeCount":313,"soonestReadout":1029},[1025],{"nctId":1026,"briefTitle":1027,"status":158,"phases":1028,"primaryCompletion":1029,"completion":1029,"start":1030,"enrollment":306,"conditions":1031,"interventions":1033},"NCT07163273","Monthly Alternating NALIRIFOX and GnP in the First-Line Setting for Metastatic Pancreatic Ductal Adenocarcinoma",[88],"2027-06-20","2025-06-20",[1032],"Pancreatic Ductal Adenocarcinoma",[1017,1034],"Gemcitabine plus nab-Paclitaxel",{"trials":1036,"activeCount":99},[],{"trials":1038,"activeCount":99},[],{"trials":1040,"activeCount":99},[],{"intervention":1034,"totalTrials":313,"cells":1042},{"EARLY_PHASE1":1043,"PHASE1":1045,"PHASE2":1047,"PHASE3":1053,"PHASE4":1055,"NA":1057},{"trials":1044,"activeCount":99},[],{"trials":1046,"activeCount":99},[],{"trials":1048,"activeCount":313,"soonestReadout":1029},[1049],{"nctId":1026,"briefTitle":1027,"status":158,"phases":1050,"primaryCompletion":1029,"completion":1029,"start":1030,"enrollment":306,"conditions":1051,"interventions":1052},[88],[1032],[1017,1034],{"trials":1054,"activeCount":99},[],{"trials":1056,"activeCount":99},[],{"trials":1058,"activeCount":99},[],{"intervention":1060,"totalTrials":180,"cells":1061},"Lidocaine",{"EARLY_PHASE1":1062,"PHASE1":1064,"PHASE2":1066,"PHASE3":1078,"PHASE4":1080,"NA":1082},{"trials":1063,"activeCount":99},[],{"trials":1065,"activeCount":99},[],{"trials":1067,"activeCount":313,"soonestReadout":1072},[1068],{"nctId":1069,"briefTitle":1070,"status":158,"phases":1071,"primaryCompletion":1072,"completion":1073,"start":1074,"enrollment":115,"conditions":1075,"interventions":1077},"NCT07061847","Bilateral Middle Meningeal Artery Lidocaine Infusion for Chronic Debilitating Migraines",[88],"2027-03-10","2027-06-30","2025-03-10",[1076],"Migraine",[1060],{"trials":1079,"activeCount":99},[],{"trials":1081,"activeCount":99},[],{"trials":1083,"activeCount":99},[1084],{"nctId":1085,"briefTitle":1086,"status":208,"phases":1087,"primaryCompletion":1088,"completion":1088,"start":1089,"enrollment":99,"conditions":1090,"interventions":1092},"NCT00823030","Effect of Intravesical Lidocaine on Urodynamic and Symptomatic Parameters of Interstitial Cystitis",[91],"2013-01","2009-01",[1091],"Interstitial Cystitis",[1060],{"intervention":40,"totalTrials":180,"cells":1094},{"EARLY_PHASE1":1095,"PHASE1":1097,"PHASE2":1099,"PHASE3":1109,"PHASE4":1111,"NA":1113},{"trials":1096,"activeCount":99},[],{"trials":1098,"activeCount":99},[],{"trials":1100,"activeCount":313,"soonestReadout":39},[1101],{"nctId":37,"briefTitle":38,"status":361,"phases":1102,"primaryCompletion":39,"completion":1103,"start":1104,"enrollment":1105,"conditions":1106,"interventions":1108},[88],"2022-06","2021-01-19",56,[1107],"Covid-19",[40],{"trials":1110,"activeCount":99},[],{"trials":1112,"activeCount":99},[],{"trials":1114,"activeCount":99},[1115],{"nctId":1116,"briefTitle":1117,"status":111,"phases":1118,"primaryCompletion":1119,"completion":1119,"start":1120,"enrollment":95,"conditions":1121,"interventions":1123},"NCT04389567","Famotidine Outpatient COVID-19 Treatment Study",[],"2020-05-25","2020-05-12",[1122],"COVID-19",[40],{"intervention":1125,"totalTrials":313,"cells":1126},"Nab-paclitaxel",{"EARLY_PHASE1":1127,"PHASE1":1129,"PHASE2":1140,"PHASE3":1142,"PHASE4":1144,"NA":1146},{"trials":1128,"activeCount":99},[],{"trials":1130,"activeCount":313,"soonestReadout":1135},[1131],{"nctId":1132,"briefTitle":1133,"status":158,"phases":1134,"primaryCompletion":1135,"completion":1135,"start":1136,"enrollment":95,"conditions":1137,"interventions":1139},"NCT07253662","Pressurized Intraperitoneal Aerosolized Chemotherapy (PIPAC) in Patients With Peritoneal Metastasis From Pancreatic Adenocarcinoma",[87],"2027-12-30","2026-12-30",[1138],"Adenocarcinoma Pancreas",[1125],{"trials":1141,"activeCount":99},[],{"trials":1143,"activeCount":99},[],{"trials":1145,"activeCount":99},[],{"trials":1147,"activeCount":99},[],{"intervention":1149,"totalTrials":313,"cells":1150},"Device Arm with Therapeutic Agents",{"EARLY_PHASE1":1151,"PHASE1":1162,"PHASE2":1164,"PHASE3":1166,"PHASE4":1168,"NA":1170},{"trials":1152,"activeCount":313,"soonestReadout":1157},[1153],{"nctId":1154,"briefTitle":1155,"status":158,"phases":1156,"primaryCompletion":1157,"completion":1157,"start":1158,"enrollment":95,"conditions":1159,"interventions":1161},"NCT07254091","Pilot Study of an Implantable Microdevice for In Situ Evaluation of Drug Response in Patients With Pancreatic Cancer",[86],"2027-01-30","2026-01-30",[1160],"Pancreatic Cancer",[1149],{"trials":1163,"activeCount":99},[],{"trials":1165,"activeCount":99},[],{"trials":1167,"activeCount":99},[],{"trials":1169,"activeCount":99},[],{"trials":1171,"activeCount":99},[],{"intervention":75,"totalTrials":313,"cells":1173},{"EARLY_PHASE1":1174,"PHASE1":1182,"PHASE2":1184,"PHASE3":1186,"PHASE4":1188,"NA":1190},{"trials":1175,"activeCount":313,"soonestReadout":74},[1176],{"nctId":72,"briefTitle":73,"status":158,"phases":1177,"primaryCompletion":74,"completion":74,"start":1178,"enrollment":95,"conditions":1179,"interventions":1181},[86],"2025-12-10",[1180],"Colorectal Cancer Metastatic",[75],{"trials":1183,"activeCount":99},[],{"trials":1185,"activeCount":99},[],{"trials":1187,"activeCount":99},[],{"trials":1189,"activeCount":99},[],{"trials":1191,"activeCount":99},[],{"intervention":1193,"totalTrials":313,"cells":1194},"Nelitolimod",{"EARLY_PHASE1":1195,"PHASE1":1206,"PHASE2":1208,"PHASE3":1210,"PHASE4":1212,"NA":1214},{"trials":1196,"activeCount":313,"soonestReadout":1201},[1197],{"nctId":1198,"briefTitle":1199,"status":158,"phases":1200,"primaryCompletion":1201,"completion":1202,"start":1203,"enrollment":95,"conditions":1204,"interventions":1205},"NCT07172282","INFINITIVE: ImmuNotherapy For PatIeNts wIth colorecTal LIVer MEtastases",[86],"2027-11-01","2028-11-01","2025-11-17",[1180],[1193],{"trials":1207,"activeCount":99},[],{"trials":1209,"activeCount":99},[],{"trials":1211,"activeCount":99},[],{"trials":1213,"activeCount":99},[],{"trials":1215,"activeCount":99},[],{"intervention":1217,"totalTrials":313,"cells":1218},"Mobilization Regimen",{"EARLY_PHASE1":1219,"PHASE1":1221,"PHASE2":1223,"PHASE3":1225,"PHASE4":1227,"NA":1229},{"trials":1220,"activeCount":99},[],{"trials":1222,"activeCount":99},[],{"trials":1224,"activeCount":99},[],{"trials":1226,"activeCount":99},[],{"trials":1228,"activeCount":99},[],{"trials":1230,"activeCount":313,"soonestReadout":1235},[1231],{"nctId":1232,"briefTitle":1233,"status":158,"phases":1234,"primaryCompletion":1235,"completion":478,"start":1236,"enrollment":95,"conditions":1237,"interventions":1239},"NCT07186179","Mobilization of CD34+ Peripheral Blood Stem Cells in Patients With Diamond Blackfan Anemia Syndrome (DBAS)",[],"2026-10-01","2026-06-01",[1238],"Diamond Blackfan Anemia",[1217],{"intervention":60,"totalTrials":313,"cells":1241},{"EARLY_PHASE1":1242,"PHASE1":1244,"PHASE2":1246,"PHASE3":1248,"PHASE4":1250,"NA":1252},{"trials":1243,"activeCount":99},[],{"trials":1245,"activeCount":99},[],{"trials":1247,"activeCount":99},[],{"trials":1249,"activeCount":99},[],{"trials":1251,"activeCount":99},[],{"trials":1253,"activeCount":313,"soonestReadout":59},[1254],{"nctId":57,"briefTitle":58,"status":158,"phases":1255,"primaryCompletion":59,"completion":1256,"start":1257,"enrollment":1258,"conditions":1259,"interventions":1262},[],"2026-12-01","2021-04-01",25,[1260,1261],"Post-Concussion Syndrome","Headache",[60],{"intervention":70,"totalTrials":313,"cells":1264},{"EARLY_PHASE1":1265,"PHASE1":1267,"PHASE2":1269,"PHASE3":1271,"PHASE4":1273,"NA":1275},{"trials":1266,"activeCount":99},[],{"trials":1268,"activeCount":99},[],{"trials":1270,"activeCount":99},[],{"trials":1272,"activeCount":99},[],{"trials":1274,"activeCount":99},[],{"trials":1276,"activeCount":313,"soonestReadout":69},[1277],{"nctId":67,"briefTitle":68,"status":361,"phases":1278,"primaryCompletion":69,"completion":1279,"start":1280,"enrollment":1281,"conditions":1282,"interventions":1284},[],"2026-10-06","2020-02-24",32,[1283],"Parkinson's Disease",[70],{"intervention":119,"totalTrials":1286,"cells":1287},5,{"EARLY_PHASE1":1288,"PHASE1":1290,"PHASE2":1292,"PHASE3":1294,"PHASE4":1296,"NA":1325},{"trials":1289,"activeCount":99},[],{"trials":1291,"activeCount":99},[],{"trials":1293,"activeCount":99},[],{"trials":1295,"activeCount":99},[],{"trials":1297,"activeCount":99},[1298,1302,1306,1310,1314],{"nctId":109,"briefTitle":110,"status":111,"phases":1299,"primaryCompletion":113,"completion":113,"start":114,"enrollment":115,"conditions":1300,"interventions":1301},[90],[24],[118,119,120,94,121,122,123],{"nctId":125,"briefTitle":126,"status":111,"phases":1303,"primaryCompletion":128,"completion":128,"start":129,"enrollment":130,"conditions":1304,"interventions":1305},[90],[15],[119,94],{"nctId":301,"briefTitle":302,"status":111,"phases":1307,"primaryCompletion":304,"completion":304,"start":305,"enrollment":306,"conditions":1308,"interventions":1309},[90],[15],[119,278],{"nctId":134,"briefTitle":135,"status":111,"phases":1311,"primaryCompletion":137,"completion":137,"start":138,"enrollment":139,"conditions":1312,"interventions":1313},[90],[15,28],[142,94,119,121,122,143,144],{"nctId":1315,"briefTitle":1316,"status":111,"phases":1317,"primaryCompletion":1318,"completion":1318,"start":1319,"enrollment":1320,"conditions":1321,"interventions":1323},"NCT00592930","Olanzapine in the Treatment of Anorexia Nervosa",[90],"2004-12","2000-06",20,[1322],"Anorexia Nervosa",[1324],"olanzapine",{"trials":1326,"activeCount":99},[],{"intervention":122,"totalTrials":279,"cells":1328},{"EARLY_PHASE1":1329,"PHASE1":1331,"PHASE2":1333,"PHASE3":1335,"PHASE4":1337,"NA":1359},{"trials":1330,"activeCount":99},[],{"trials":1332,"activeCount":99},[],{"trials":1334,"activeCount":99},[],{"trials":1336,"activeCount":99},[],{"trials":1338,"activeCount":99},[1339,1343,1347],{"nctId":109,"briefTitle":110,"status":111,"phases":1340,"primaryCompletion":113,"completion":113,"start":114,"enrollment":115,"conditions":1341,"interventions":1342},[90],[24],[118,119,120,94,121,122,123],{"nctId":134,"briefTitle":135,"status":111,"phases":1344,"primaryCompletion":137,"completion":137,"start":138,"enrollment":139,"conditions":1345,"interventions":1346},[90],[15,28],[142,94,119,121,122,143,144],{"nctId":1348,"briefTitle":1349,"status":258,"phases":1350,"primaryCompletion":1351,"completion":1351,"start":221,"enrollment":1352,"conditions":1353,"interventions":1357},"NCT01844700","1\u002F2-MC4R Genotype and Pediatric Antipsychotic Drug- Induced Weight Gain",[90],"2014-04",14,[1354,1355,1356],"High Risk MC4R Genotype","Low Risk MC4R Genotype","One Week or Less Antipsychotic Lifetime Exposure",[122,1358],"aripiprazole, quetiapine, or risperidone",{"trials":1360,"activeCount":99},[],{"intervention":1362,"totalTrials":279,"cells":1363},"Bupivacaine",{"EARLY_PHASE1":1364,"PHASE1":1375,"PHASE2":1377,"PHASE3":1379,"PHASE4":1391,"NA":1403},{"trials":1365,"activeCount":99},[1366],{"nctId":1367,"briefTitle":1368,"status":258,"phases":1369,"primaryCompletion":1370,"completion":1370,"start":1371,"enrollment":22,"conditions":1372,"interventions":1374},"NCT04101682","Continuous Vs Single Shot Block After ACL",[86],"2022-05-17","2020-09-25",[1373],"ACL Injury",[1362],{"trials":1376,"activeCount":99},[],{"trials":1378,"activeCount":99},[],{"trials":1380,"activeCount":99},[1381],{"nctId":1382,"briefTitle":1383,"status":208,"phases":1384,"primaryCompletion":1385,"completion":1385,"start":1385,"enrollment":99,"conditions":1386,"interventions":1388},"NCT03043027","Efficacy of Liposomal Bupivacaine for Pain Control After Percutaneous Nephrostolithotomy",[89],"2017-08-08",[1387,460],"Renal Calculi",[1389,1362,1390],"liposomal bupivicaine","Saline Solution",{"trials":1392,"activeCount":99},[1393],{"nctId":1394,"briefTitle":1395,"status":111,"phases":1396,"primaryCompletion":1397,"completion":1398,"start":1399,"enrollment":1400,"conditions":1401,"interventions":1402},"NCT04996251","Pre-incision Versus Post-incision Local Anesthetic During Robotic Sacrocolpopexy",[90],"2023-05-30","2023-06-30","2021-07-30",129,[410],[1362],{"trials":1404,"activeCount":99},[],{"intervention":121,"totalTrials":180,"cells":1406},{"EARLY_PHASE1":1407,"PHASE1":1409,"PHASE2":1411,"PHASE3":1413,"PHASE4":1415,"NA":1425},{"trials":1408,"activeCount":99},[],{"trials":1410,"activeCount":99},[],{"trials":1412,"activeCount":99},[],{"trials":1414,"activeCount":99},[],{"trials":1416,"activeCount":99},[1417,1421],{"nctId":109,"briefTitle":110,"status":111,"phases":1418,"primaryCompletion":113,"completion":113,"start":114,"enrollment":115,"conditions":1419,"interventions":1420},[90],[24],[118,119,120,94,121,122,123],{"nctId":134,"briefTitle":135,"status":111,"phases":1422,"primaryCompletion":137,"completion":137,"start":138,"enrollment":139,"conditions":1423,"interventions":1424},[90],[15,28],[142,94,119,121,122,143,144],{"trials":1426,"activeCount":99},[],{"intervention":1428,"totalTrials":313,"cells":1429},"Synera",{"EARLY_PHASE1":1430,"PHASE1":1432,"PHASE2":1434,"PHASE3":1436,"PHASE4":1438,"NA":1450},{"trials":1431,"activeCount":99},[],{"trials":1433,"activeCount":99},[],{"trials":1435,"activeCount":99},[],{"trials":1437,"activeCount":99},[],{"trials":1439,"activeCount":99},[1440],{"nctId":1441,"briefTitle":1442,"status":208,"phases":1443,"primaryCompletion":1444,"completion":1444,"start":1445,"enrollment":99,"conditions":1446,"interventions":1449},"NCT01775605","Study of Use of Synera for Pain During Local Skin Infiltration With Lidocaine Before Epidural Placement",[90],"2014-11","2013-11",[1447,1448],"Pain","Anxiety",[1428],{"trials":1451,"activeCount":99},[],{"intervention":1453,"totalTrials":313,"cells":1454},"empagliflozin",{"EARLY_PHASE1":1455,"PHASE1":1457,"PHASE2":1459,"PHASE3":1461,"PHASE4":1463,"NA":1478},{"trials":1456,"activeCount":99},[],{"trials":1458,"activeCount":99},[],{"trials":1460,"activeCount":99},[],{"trials":1462,"activeCount":99},[],{"trials":1464,"activeCount":99},[1465],{"nctId":1466,"briefTitle":1467,"status":208,"phases":1468,"primaryCompletion":1469,"completion":1470,"start":1471,"enrollment":99,"conditions":1472,"interventions":1476},"NCT02768220","The Effect of Sodium-Glucose Cotransporter 2 Inhibitors on Advanced Glycation End Products",[90],"2018-08","2018-12","2017-12-01",[1473,1474,1475],"SGLT-2 Inhibitors","Advanced Glycation End Products","Diabetes",[1453,1477],"linagliptin",{"trials":1479,"activeCount":99},[],{"intervention":1477,"totalTrials":313,"cells":1481},{"EARLY_PHASE1":1482,"PHASE1":1484,"PHASE2":1486,"PHASE3":1488,"PHASE4":1490,"NA":1496},{"trials":1483,"activeCount":99},[],{"trials":1485,"activeCount":99},[],{"trials":1487,"activeCount":99},[],{"trials":1489,"activeCount":99},[],{"trials":1491,"activeCount":99},[1492],{"nctId":1466,"briefTitle":1467,"status":208,"phases":1493,"primaryCompletion":1469,"completion":1470,"start":1471,"enrollment":99,"conditions":1494,"interventions":1495},[90],[1473,1474,1475],[1453,1477],{"trials":1497,"activeCount":99},[],{"intervention":118,"totalTrials":313,"cells":1499},{"EARLY_PHASE1":1500,"PHASE1":1502,"PHASE2":1504,"PHASE3":1506,"PHASE4":1508,"NA":1514},{"trials":1501,"activeCount":99},[],{"trials":1503,"activeCount":99},[],{"trials":1505,"activeCount":99},[],{"trials":1507,"activeCount":99},[],{"trials":1509,"activeCount":99},[1510],{"nctId":109,"briefTitle":110,"status":111,"phases":1511,"primaryCompletion":113,"completion":113,"start":114,"enrollment":115,"conditions":1512,"interventions":1513},[90],[24],[118,119,120,94,121,122,123],{"trials":1515,"activeCount":99},[],{"intervention":120,"totalTrials":313,"cells":1517},{"EARLY_PHASE1":1518,"PHASE1":1520,"PHASE2":1522,"PHASE3":1524,"PHASE4":1526,"NA":1532},{"trials":1519,"activeCount":99},[],{"trials":1521,"activeCount":99},[],{"trials":1523,"activeCount":99},[],{"trials":1525,"activeCount":99},[],{"trials":1527,"activeCount":99},[1528],{"nctId":109,"briefTitle":110,"status":111,"phases":1529,"primaryCompletion":113,"completion":113,"start":114,"enrollment":115,"conditions":1530,"interventions":1531},[90],[24],[118,119,120,94,121,122,123],{"trials":1533,"activeCount":99},[],{"intervention":123,"totalTrials":313,"cells":1535},{"EARLY_PHASE1":1536,"PHASE1":1538,"PHASE2":1540,"PHASE3":1542,"PHASE4":1544,"NA":1550},{"trials":1537,"activeCount":99},[],{"trials":1539,"activeCount":99},[],{"trials":1541,"activeCount":99},[],{"trials":1543,"activeCount":99},[],{"trials":1545,"activeCount":99},[1546],{"nctId":109,"briefTitle":110,"status":111,"phases":1547,"primaryCompletion":113,"completion":113,"start":114,"enrollment":115,"conditions":1548,"interventions":1549},[90],[24],[118,119,120,94,121,122,123],{"trials":1551,"activeCount":99},[],{"intervention":1553,"totalTrials":313,"cells":1554},"Bupivicaine HCl",{"EARLY_PHASE1":1555,"PHASE1":1557,"PHASE2":1559,"PHASE3":1561,"PHASE4":1563,"NA":1578},{"trials":1556,"activeCount":99},[],{"trials":1558,"activeCount":99},[],{"trials":1560,"activeCount":99},[],{"trials":1562,"activeCount":99},[],{"trials":1564,"activeCount":99},[1565],{"nctId":1566,"briefTitle":1567,"status":258,"phases":1568,"primaryCompletion":1569,"completion":1569,"start":1570,"enrollment":11,"conditions":1571,"interventions":1576},"NCT02865928","Serratus Plane Block for Postoperative Pain Control",[90],"2019-11-25","2017-09-05",[1572,1573,1574,1575],"Outpatient Breast Surgery","Mastopexy","Augmentation","Revision",[1553,1577],"Normal Saline",{"trials":1579,"activeCount":99},[],{"intervention":1577,"totalTrials":313,"cells":1581},{"EARLY_PHASE1":1582,"PHASE1":1584,"PHASE2":1586,"PHASE3":1588,"PHASE4":1590,"NA":1596},{"trials":1583,"activeCount":99},[],{"trials":1585,"activeCount":99},[],{"trials":1587,"activeCount":99},[],{"trials":1589,"activeCount":99},[],{"trials":1591,"activeCount":99},[1592],{"nctId":1566,"briefTitle":1567,"status":258,"phases":1593,"primaryCompletion":1569,"completion":1569,"start":1570,"enrollment":11,"conditions":1594,"interventions":1595},[90],[1572,1573,1574,1575],[1553,1577],{"trials":1597,"activeCount":99},[],{"intervention":1599,"totalTrials":313,"cells":1600},"memantine",{"EARLY_PHASE1":1601,"PHASE1":1603,"PHASE2":1605,"PHASE3":1607,"PHASE4":1609,"NA":1621},{"trials":1602,"activeCount":99},[],{"trials":1604,"activeCount":99},[],{"trials":1606,"activeCount":99},[],{"trials":1608,"activeCount":99},[],{"trials":1610,"activeCount":99},[1611],{"nctId":1612,"briefTitle":1613,"status":111,"phases":1614,"primaryCompletion":1615,"completion":1615,"start":1616,"enrollment":1617,"conditions":1618,"interventions":1620},"NCT00551161","Magnetic Resonance Spectroscopy Study of Memantine in Alzheimer's Disease",[90],"2011-12","2007-08",12,[1619],"Alzheimer Disease",[1599],{"trials":1622,"activeCount":99},[],{"intervention":1624,"totalTrials":313,"cells":1625},"Midodrine",{"EARLY_PHASE1":1626,"PHASE1":1628,"PHASE2":1630,"PHASE3":1632,"PHASE4":1634,"NA":1647},{"trials":1627,"activeCount":99},[],{"trials":1629,"activeCount":99},[],{"trials":1631,"activeCount":99},[],{"trials":1633,"activeCount":99},[],{"trials":1635,"activeCount":99},[1636],{"nctId":1637,"briefTitle":1638,"status":208,"phases":1639,"primaryCompletion":1640,"completion":1640,"start":1641,"enrollment":99,"conditions":1642,"interventions":1646},"NCT02771158","Midodrine During Recovery From Septic Shock",[90],"2017-11-01","2017-08",[1643,1644,1645],"Hypotension","Shock, Septic","Sepsis",[1624],{"trials":1648,"activeCount":99},[],{"intervention":1650,"totalTrials":313,"cells":1651},"long-acting injectable risperidone",{"EARLY_PHASE1":1652,"PHASE1":1654,"PHASE2":1656,"PHASE3":1658,"PHASE4":1660,"NA":1670},{"trials":1653,"activeCount":99},[],{"trials":1655,"activeCount":99},[],{"trials":1657,"activeCount":99},[],{"trials":1659,"activeCount":99},[],{"trials":1661,"activeCount":99},[1662],{"nctId":1663,"briefTitle":1664,"status":258,"phases":1665,"primaryCompletion":1445,"completion":1445,"start":1666,"enrollment":313,"conditions":1667,"interventions":1669},"NCT00314327","Optimizing Response in Psychosis Study",[90],"2006-04",[15,28,1668,202],"Schizophreniform Disorder",[1650],{"trials":1671,"activeCount":99},[],{"intervention":1673,"totalTrials":313,"cells":1674},"Vortioxetine",{"EARLY_PHASE1":1675,"PHASE1":1677,"PHASE2":1679,"PHASE3":1681,"PHASE4":1683,"NA":1695},{"trials":1676,"activeCount":99},[],{"trials":1678,"activeCount":99},[],{"trials":1680,"activeCount":99},[],{"trials":1682,"activeCount":99},[],{"trials":1684,"activeCount":99},[1685],{"nctId":1686,"briefTitle":1687,"status":1688,"phases":1689,"primaryCompletion":1690,"completion":1691,"start":211,"enrollment":200,"conditions":1692,"interventions":1694},"NCT02357797","Adjunctive Vortioxetine in Schizophrenia","UNKNOWN",[90],"2023-10-01","2024-06-01",[15,1693],"Negative Symptoms",[1673],{"trials":1696,"activeCount":99},[],{"intervention":142,"totalTrials":313,"cells":1698},{"EARLY_PHASE1":1699,"PHASE1":1701,"PHASE2":1703,"PHASE3":1705,"PHASE4":1707,"NA":1713},{"trials":1700,"activeCount":99},[],{"trials":1702,"activeCount":99},[],{"trials":1704,"activeCount":99},[],{"trials":1706,"activeCount":99},[],{"trials":1708,"activeCount":99},[1709],{"nctId":134,"briefTitle":135,"status":111,"phases":1710,"primaryCompletion":137,"completion":137,"start":138,"enrollment":139,"conditions":1711,"interventions":1712},[90],[15,28],[142,94,119,121,122,143,144],{"trials":1714,"activeCount":99},[],{"intervention":144,"totalTrials":313,"cells":1716},{"EARLY_PHASE1":1717,"PHASE1":1719,"PHASE2":1721,"PHASE3":1723,"PHASE4":1725,"NA":1731},{"trials":1718,"activeCount":99},[],{"trials":1720,"activeCount":99},[],{"trials":1722,"activeCount":99},[],{"trials":1724,"activeCount":99},[],{"trials":1726,"activeCount":99},[1727],{"nctId":134,"briefTitle":135,"status":111,"phases":1728,"primaryCompletion":137,"completion":137,"start":138,"enrollment":139,"conditions":1729,"interventions":1730},[90],[15,28],[142,94,119,121,122,143,144],{"trials":1732,"activeCount":99},[],{"intervention":1358,"totalTrials":313,"cells":1734},{"EARLY_PHASE1":1735,"PHASE1":1737,"PHASE2":1739,"PHASE3":1741,"PHASE4":1743,"NA":1749},{"trials":1736,"activeCount":99},[],{"trials":1738,"activeCount":99},[],{"trials":1740,"activeCount":99},[],{"trials":1742,"activeCount":99},[],{"trials":1744,"activeCount":99},[1745],{"nctId":1348,"briefTitle":1349,"status":258,"phases":1746,"primaryCompletion":1351,"completion":1351,"start":221,"enrollment":1352,"conditions":1747,"interventions":1748},[90],[1354,1355,1356],[122,1358],{"trials":1750,"activeCount":99},[],{"intervention":1752,"totalTrials":313,"cells":1753},"Valproic acid",{"EARLY_PHASE1":1754,"PHASE1":1756,"PHASE2":1758,"PHASE3":1760,"PHASE4":1762,"NA":1776},{"trials":1755,"activeCount":99},[],{"trials":1757,"activeCount":99},[],{"trials":1759,"activeCount":99},[],{"trials":1761,"activeCount":99},[],{"trials":1763,"activeCount":99},[1764],{"nctId":1765,"briefTitle":1766,"status":258,"phases":1767,"completion":1768,"start":1769,"enrollment":1770,"conditions":1771,"interventions":1775},"NCT00298857","A Pharmacokinetic Study to Compare the Dosing of Valproic Acid in Subjects With Different Body Weights",[90],"2007-03","2006-03",22,[1772,1773,1774],"Healthy","Obesity","Pharmacokinetics",[1752],{"trials":1777,"activeCount":99},[],{"intervention":1779,"totalTrials":313,"cells":1780},"Liposome Bupivacaine",{"EARLY_PHASE1":1781,"PHASE1":1783,"PHASE2":1785,"PHASE3":1787,"PHASE4":1789,"NA":1801},{"trials":1782,"activeCount":99},[],{"trials":1784,"activeCount":99},[],{"trials":1786,"activeCount":99},[],{"trials":1788,"activeCount":99},[],{"trials":1790,"activeCount":99},[1791],{"nctId":1792,"briefTitle":1793,"status":111,"phases":1794,"primaryCompletion":1795,"completion":1796,"start":1444,"enrollment":525,"conditions":1797,"interventions":1799},"NCT02274870","Liposomal Bupivacaine for Post Operative Pain After Knee Replacement Surgery",[90],"2016-12","2017-01",[1798],"Post-operative Pain",[1779,1800],"Bupivacaine HCl",{"trials":1802,"activeCount":99},[],{"intervention":1800,"totalTrials":313,"cells":1804},{"EARLY_PHASE1":1805,"PHASE1":1807,"PHASE2":1809,"PHASE3":1811,"PHASE4":1813,"NA":1819},{"trials":1806,"activeCount":99},[],{"trials":1808,"activeCount":99},[],{"trials":1810,"activeCount":99},[],{"trials":1812,"activeCount":99},[],{"trials":1814,"activeCount":99},[1815],{"nctId":1792,"briefTitle":1793,"status":111,"phases":1816,"primaryCompletion":1795,"completion":1796,"start":1444,"enrollment":525,"conditions":1817,"interventions":1818},[90],[1798],[1779,1800],{"trials":1820,"activeCount":99},[],{"intervention":1822,"totalTrials":313,"cells":1823},"Ketamine",{"EARLY_PHASE1":1824,"PHASE1":1826,"PHASE2":1828,"PHASE3":1830,"PHASE4":1832,"NA":1846},{"trials":1825,"activeCount":99},[],{"trials":1827,"activeCount":99},[],{"trials":1829,"activeCount":99},[],{"trials":1831,"activeCount":99},[],{"trials":1833,"activeCount":99},[1834],{"nctId":1835,"briefTitle":1836,"status":111,"phases":1837,"primaryCompletion":1838,"completion":1839,"start":1840,"enrollment":365,"conditions":1841,"interventions":1844},"NCT01881763","Ketamine as an Augmentation Strategy for Electroconvulsive Therapy (ECT) in Depression",[90],"2017-03","2017-07","2010-06",[1842,1843],"Unipolar Depression","Bipolar Depression",[1822,1845],"Methohexital",{"trials":1847,"activeCount":99},[],{"intervention":1845,"totalTrials":313,"cells":1849},{"EARLY_PHASE1":1850,"PHASE1":1852,"PHASE2":1854,"PHASE3":1856,"PHASE4":1858,"NA":1864},{"trials":1851,"activeCount":99},[],{"trials":1853,"activeCount":99},[],{"trials":1855,"activeCount":99},[],{"trials":1857,"activeCount":99},[],{"trials":1859,"activeCount":99},[1860],{"nctId":1835,"briefTitle":1836,"status":111,"phases":1861,"primaryCompletion":1838,"completion":1839,"start":1840,"enrollment":365,"conditions":1862,"interventions":1863},[90],[1842,1843],[1822,1845],{"trials":1865,"activeCount":99},[],{"intervention":1867,"totalTrials":313,"cells":1868},"Opioid Free Total Intravenous Anesthesia",{"EARLY_PHASE1":1869,"PHASE1":1871,"PHASE2":1873,"PHASE3":1875,"PHASE4":1877,"NA":1890},{"trials":1870,"activeCount":99},[],{"trials":1872,"activeCount":99},[],{"trials":1874,"activeCount":99},[],{"trials":1876,"activeCount":99},[],{"trials":1878,"activeCount":99},[1879],{"nctId":1880,"briefTitle":1881,"status":111,"phases":1882,"primaryCompletion":1883,"completion":1883,"start":1884,"enrollment":1885,"conditions":1886,"interventions":1888},"NCT04144153","Opioid Free Anesthesia and Bariatric Surgery",[90],"2023-09-01","2021-08-09",58,[1887],"Postoperative Quality of Recovery",[1867,1889],"Total Intravenous anesthesia with opioid",{"trials":1891,"activeCount":99},[],{"intervention":1889,"totalTrials":313,"cells":1893},{"EARLY_PHASE1":1894,"PHASE1":1896,"PHASE2":1898,"PHASE3":1900,"PHASE4":1902,"NA":1908},{"trials":1895,"activeCount":99},[],{"trials":1897,"activeCount":99},[],{"trials":1899,"activeCount":99},[],{"trials":1901,"activeCount":99},[],{"trials":1903,"activeCount":99},[1904],{"nctId":1880,"briefTitle":1881,"status":111,"phases":1905,"primaryCompletion":1883,"completion":1883,"start":1884,"enrollment":1885,"conditions":1906,"interventions":1907},[90],[1887],[1867,1889],{"trials":1909,"activeCount":99},[],{"intervention":1911,"totalTrials":313,"cells":1912},"pramipexole",{"EARLY_PHASE1":1913,"PHASE1":1915,"PHASE2":1917,"PHASE3":1919,"PHASE4":1921,"NA":1932},{"trials":1914,"activeCount":99},[],{"trials":1916,"activeCount":99},[],{"trials":1918,"activeCount":99},[],{"trials":1920,"activeCount":99},[],{"trials":1922,"activeCount":99},[1923],{"nctId":1924,"briefTitle":1925,"status":111,"phases":1926,"primaryCompletion":1927,"completion":1927,"start":1928,"enrollment":1929,"conditions":1930,"interventions":1931},"NCT00597896","Cognitive Enhancement in Bipolar Disorder",[90],"2011-04","2005-10",50,[24],[1911],{"trials":1933,"activeCount":99},[],{"intervention":1935,"totalTrials":313,"cells":1936},"IV Acetaminophen",{"EARLY_PHASE1":1937,"PHASE1":1939,"PHASE2":1941,"PHASE3":1943,"PHASE4":1945,"NA":1959},{"trials":1938,"activeCount":99},[],{"trials":1940,"activeCount":99},[],{"trials":1942,"activeCount":99},[],{"trials":1944,"activeCount":99},[],{"trials":1946,"activeCount":99},[1947],{"nctId":1948,"briefTitle":1949,"status":258,"phases":1950,"primaryCompletion":1951,"completion":1951,"start":1952,"enrollment":1953,"conditions":1954,"interventions":1957},"NCT01798316","IV Acetaminophen for Postoperative Analgesia",[90],"2015-09","2013-03",105,[460,1955,1956],"Postoperative Nausea","Postoperative Vomiting",[1935,1958],"Standard of Care",{"trials":1960,"activeCount":99},[],{"intervention":1958,"totalTrials":313,"cells":1962},{"EARLY_PHASE1":1963,"PHASE1":1965,"PHASE2":1967,"PHASE3":1969,"PHASE4":1971,"NA":1977},{"trials":1964,"activeCount":99},[],{"trials":1966,"activeCount":99},[],{"trials":1968,"activeCount":99},[],{"trials":1970,"activeCount":99},[],{"trials":1972,"activeCount":99},[1973],{"nctId":1948,"briefTitle":1949,"status":258,"phases":1974,"primaryCompletion":1951,"completion":1951,"start":1952,"enrollment":1953,"conditions":1975,"interventions":1976},[90],[460,1955,1956],[1935,1958],{"trials":1978,"activeCount":99},[],{"intervention":1980,"totalTrials":313,"cells":1981},"Polyethylene Glycol Powder",{"EARLY_PHASE1":1982,"PHASE1":1984,"PHASE2":1986,"PHASE3":1988,"PHASE4":1990,"NA":2003},{"trials":1983,"activeCount":99},[],{"trials":1985,"activeCount":99},[],{"trials":1987,"activeCount":99},[],{"trials":1989,"activeCount":99},[],{"trials":1991,"activeCount":99},[1992],{"nctId":1993,"briefTitle":1994,"status":111,"phases":1995,"primaryCompletion":1996,"completion":1996,"start":1997,"enrollment":1998,"conditions":1999,"interventions":2002},"NCT04197869","Does a Preoperative Bowel Regimen Change Time to First Bowel Movement After Robotic Sacral Colpopexy",[90],"2023-06-21","2019-12-09",71,[2000,2001],"Constipation","Post-Op Complication",[1980],{"trials":2004,"activeCount":99},[],{"intervention":2006,"totalTrials":313,"cells":2007},"Naproxen",{"EARLY_PHASE1":2008,"PHASE1":2010,"PHASE2":2012,"PHASE3":2014,"PHASE4":2016,"NA":2025},{"trials":2009,"activeCount":99},[],{"trials":2011,"activeCount":99},[],{"trials":2013,"activeCount":99},[],{"trials":2015,"activeCount":99},[],{"trials":2017,"activeCount":99},[2018],{"nctId":2019,"briefTitle":2020,"status":208,"phases":2021,"primaryCompletion":150,"completion":150,"start":149,"enrollment":99,"conditions":2022,"interventions":2024},"NCT02281968","NSAIDs for Pain After Ankle Fracture Surgery",[90],[2023],"Closed Fracture of Ankle",[2006],{"trials":2026,"activeCount":99},[],{"intervention":265,"totalTrials":313,"cells":2028},{"EARLY_PHASE1":2029,"PHASE1":2031,"PHASE2":2033,"PHASE3":2035,"PHASE4":2037,"NA":2043},{"trials":2030,"activeCount":99},[],{"trials":2032,"activeCount":99},[],{"trials":2034,"activeCount":99},[],{"trials":2036,"activeCount":99},[],{"trials":2038,"activeCount":99},[2039],{"nctId":256,"briefTitle":257,"status":258,"phases":2040,"primaryCompletion":260,"completion":260,"start":261,"enrollment":22,"conditions":2041,"interventions":2042},[90],[263],[143,265],{"trials":2044,"activeCount":99},[],{"intervention":2046,"totalTrials":313,"cells":2047},"Lithium treatment in combination with a SGA",{"EARLY_PHASE1":2048,"PHASE1":2050,"PHASE2":2052,"PHASE3":2054,"PHASE4":2056,"NA":2067},{"trials":2049,"activeCount":99},[],{"trials":2051,"activeCount":99},[],{"trials":2053,"activeCount":99},[],{"trials":2055,"activeCount":99},[],{"trials":2057,"activeCount":99},[2058],{"nctId":2059,"briefTitle":2060,"status":208,"phases":2061,"primaryCompletion":2062,"completion":1951,"start":2063,"enrollment":99,"conditions":2064,"interventions":2066},"NCT01495156","Study of the Efficacy of Adjunctive Lithium Treatment for the Treatment of Psychotic Mania",[90],"2014-09","2011-09",[2065],"Bipolar I Disorder",[2046],{"trials":2068,"activeCount":99},[],{"intervention":2070,"totalTrials":313,"cells":2071},"Arixtra alone",{"EARLY_PHASE1":2072,"PHASE1":2074,"PHASE2":2076,"PHASE3":2078,"PHASE4":2089,"NA":2091},{"trials":2073,"activeCount":99},[],{"trials":2075,"activeCount":99},[],{"trials":2077,"activeCount":99},[],{"trials":2079,"activeCount":99},[2080],{"nctId":2081,"briefTitle":2082,"status":258,"phases":2083,"primaryCompletion":2084,"completion":2084,"start":2085,"enrollment":2086,"conditions":2087,"interventions":2088},"NCT00423683","Anticoagulation and Inferior Vena Cava Filters in Cancer Patients With a Venous Thromboembolism",[89],"2010-11","2007-01",64,[820,369],[2070],{"trials":2090,"activeCount":99},[],{"trials":2092,"activeCount":99},[],{"intervention":2094,"totalTrials":313,"cells":2095},"New Medication: Enalapril, Isradipine, Propranolol",{"EARLY_PHASE1":2096,"PHASE1":2098,"PHASE2":2100,"PHASE3":2102,"PHASE4":2114,"NA":2116},{"trials":2097,"activeCount":99},[],{"trials":2099,"activeCount":99},[],{"trials":2101,"activeCount":99},[],{"trials":2103,"activeCount":99},[2104],{"nctId":2105,"briefTitle":2106,"status":111,"phases":2107,"primaryCompletion":2108,"completion":2109,"start":2110,"enrollment":570,"conditions":2111,"interventions":2113},"NCT01007994","Reduction of Night-time Blood Pressure in Pediatric Renal Transplant Recipients",[88,89],"2020-01","2020-08","2009-11",[2112],"Hypertension Secondary to Kidney Transplant",[2094],{"trials":2115,"activeCount":99},[],{"trials":2117,"activeCount":99},[],{"intervention":1389,"totalTrials":313,"cells":2119},{"EARLY_PHASE1":2120,"PHASE1":2122,"PHASE2":2124,"PHASE3":2126,"PHASE4":2132,"NA":2134},{"trials":2121,"activeCount":99},[],{"trials":2123,"activeCount":99},[],{"trials":2125,"activeCount":99},[],{"trials":2127,"activeCount":99},[2128],{"nctId":1382,"briefTitle":1383,"status":208,"phases":2129,"primaryCompletion":1385,"completion":1385,"start":1385,"enrollment":99,"conditions":2130,"interventions":2131},[89],[1387,460],[1389,1362,1390],{"trials":2133,"activeCount":99},[],{"trials":2135,"activeCount":99},[],{"intervention":1390,"totalTrials":313,"cells":2137},{"EARLY_PHASE1":2138,"PHASE1":2140,"PHASE2":2142,"PHASE3":2144,"PHASE4":2150,"NA":2152},{"trials":2139,"activeCount":99},[],{"trials":2141,"activeCount":99},[],{"trials":2143,"activeCount":99},[],{"trials":2145,"activeCount":99},[2146],{"nctId":1382,"briefTitle":1383,"status":208,"phases":2147,"primaryCompletion":1385,"completion":1385,"start":1385,"enrollment":99,"conditions":2148,"interventions":2149},[89],[1387,460],[1389,1362,1390],{"trials":2151,"activeCount":99},[],{"trials":2153,"activeCount":99},[],{"intervention":2155,"totalTrials":313,"cells":2156},"Budesonide",{"EARLY_PHASE1":2157,"PHASE1":2159,"PHASE2":2161,"PHASE3":2163,"PHASE4":2178,"NA":2180},{"trials":2158,"activeCount":99},[],{"trials":2160,"activeCount":99},[],{"trials":2162,"activeCount":99},[],{"trials":2164,"activeCount":99},[2165],{"nctId":2166,"briefTitle":2167,"status":111,"phases":2168,"primaryCompletion":2169,"completion":2169,"start":2170,"enrollment":2171,"conditions":2172,"interventions":2174},"NCT00588406","Study of Budesonide as an Addition to Standard Therapy in Adult Asthmatics in the Emergency Room.",[89],"2009-12","2007-09",95,[2173],"Asthma",[2155,2175,2176,2177],"albuterol","Ipratropium bromide","Prednisone",{"trials":2179,"activeCount":99},[],{"trials":2181,"activeCount":99},[],{"intervention":2175,"totalTrials":313,"cells":2183},{"EARLY_PHASE1":2184,"PHASE1":2186,"PHASE2":2188,"PHASE3":2190,"PHASE4":2196,"NA":2198},{"trials":2185,"activeCount":99},[],{"trials":2187,"activeCount":99},[],{"trials":2189,"activeCount":99},[],{"trials":2191,"activeCount":99},[2192],{"nctId":2166,"briefTitle":2167,"status":111,"phases":2193,"primaryCompletion":2169,"completion":2169,"start":2170,"enrollment":2171,"conditions":2194,"interventions":2195},[89],[2173],[2155,2175,2176,2177],{"trials":2197,"activeCount":99},[],{"trials":2199,"activeCount":99},[],{"intervention":2176,"totalTrials":313,"cells":2201},{"EARLY_PHASE1":2202,"PHASE1":2204,"PHASE2":2206,"PHASE3":2208,"PHASE4":2214,"NA":2216},{"trials":2203,"activeCount":99},[],{"trials":2205,"activeCount":99},[],{"trials":2207,"activeCount":99},[],{"trials":2209,"activeCount":99},[2210],{"nctId":2166,"briefTitle":2167,"status":111,"phases":2211,"primaryCompletion":2169,"completion":2169,"start":2170,"enrollment":2171,"conditions":2212,"interventions":2213},[89],[2173],[2155,2175,2176,2177],{"trials":2215,"activeCount":99},[],{"trials":2217,"activeCount":99},[],{"intervention":2177,"totalTrials":313,"cells":2219},{"EARLY_PHASE1":2220,"PHASE1":2222,"PHASE2":2224,"PHASE3":2226,"PHASE4":2232,"NA":2234},{"trials":2221,"activeCount":99},[],{"trials":2223,"activeCount":99},[],{"trials":2225,"activeCount":99},[],{"trials":2227,"activeCount":99},[2228],{"nctId":2166,"briefTitle":2167,"status":111,"phases":2229,"primaryCompletion":2169,"completion":2169,"start":2170,"enrollment":2171,"conditions":2230,"interventions":2231},[89],[2173],[2155,2175,2176,2177],{"trials":2233,"activeCount":99},[],{"trials":2235,"activeCount":99},[],{"intervention":2237,"totalTrials":313,"cells":2238},"Enoxaparin",{"EARLY_PHASE1":2239,"PHASE1":2241,"PHASE2":2243,"PHASE3":2245,"PHASE4":2259,"NA":2261},{"trials":2240,"activeCount":99},[],{"trials":2242,"activeCount":99},[],{"trials":2244,"activeCount":99},[],{"trials":2246,"activeCount":99},[2247],{"nctId":2248,"briefTitle":2249,"status":111,"phases":2250,"primaryCompletion":2251,"completion":2251,"start":2252,"enrollment":2253,"conditions":2254,"interventions":2257},"NCT04401293","Full Dose Heparin Vs. Prophylactic Or Intermediate Dose Heparin in High Risk COVID-19 Patients",[89],"2021-05-14","2020-04-26",257,[2255,2256],"Sars-CoV2","COVID",[2237,2258],"Prophylactic\u002FIntermediate Dose Enoxaparin",{"trials":2260,"activeCount":99},[],{"trials":2262,"activeCount":99},[],{"intervention":2258,"totalTrials":313,"cells":2264},{"EARLY_PHASE1":2265,"PHASE1":2267,"PHASE2":2269,"PHASE3":2271,"PHASE4":2277,"NA":2279},{"trials":2266,"activeCount":99},[],{"trials":2268,"activeCount":99},[],{"trials":2270,"activeCount":99},[],{"trials":2272,"activeCount":99},[2273],{"nctId":2248,"briefTitle":2249,"status":111,"phases":2274,"primaryCompletion":2251,"completion":2251,"start":2252,"enrollment":2253,"conditions":2275,"interventions":2276},[89],[2255,2256],[2237,2258],{"trials":2278,"activeCount":99},[],{"trials":2280,"activeCount":99},[],{"intervention":2282,"totalTrials":313,"cells":2283},"Somatropin",{"EARLY_PHASE1":2284,"PHASE1":2286,"PHASE2":2288,"PHASE3":2290,"PHASE4":2304,"NA":2306},{"trials":2285,"activeCount":99},[],{"trials":2287,"activeCount":99},[],{"trials":2289,"activeCount":99},[],{"trials":2291,"activeCount":99},[2292],{"nctId":2293,"briefTitle":2294,"status":1688,"phases":2295,"primaryCompletion":2296,"completion":1178,"start":2297,"enrollment":1929,"conditions":2298,"interventions":2303},"NCT06103513","Randomized Clinical Trial of Two Different Initial Growth Hormone Doses in Children",[89],"2025-06-10","2023-12-10",[2299,2300,2301,2302],"Growth Disorders","Growth Failure","Growth Hormone Treatment","Growth",[2282],{"trials":2305,"activeCount":99},[],{"trials":2307,"activeCount":99},[],{"intervention":2309,"totalTrials":313,"cells":2310},"SOC + Intravenous Famotidine",{"EARLY_PHASE1":2311,"PHASE1":2313,"PHASE2":2315,"PHASE3":2317,"PHASE4":2329,"NA":2331},{"trials":2312,"activeCount":99},[],{"trials":2314,"activeCount":99},[],{"trials":2316,"activeCount":99},[],{"trials":2318,"activeCount":99},[2319],{"nctId":2320,"briefTitle":2321,"status":111,"phases":2322,"primaryCompletion":2323,"completion":2323,"start":2324,"enrollment":2325,"conditions":2326,"interventions":2327},"NCT04370262","Multi-site Adaptive Trials for COVID-19",[89],"2020-09-07","2020-04-07",233,[1122],[2309,2328],"SOC + Placebo",{"trials":2330,"activeCount":99},[],{"trials":2332,"activeCount":99},[],{"intervention":2328,"totalTrials":313,"cells":2334},{"EARLY_PHASE1":2335,"PHASE1":2337,"PHASE2":2339,"PHASE3":2341,"PHASE4":2347,"NA":2349},{"trials":2336,"activeCount":99},[],{"trials":2338,"activeCount":99},[],{"trials":2340,"activeCount":99},[],{"trials":2342,"activeCount":99},[2343],{"nctId":2320,"briefTitle":2321,"status":111,"phases":2344,"primaryCompletion":2323,"completion":2323,"start":2324,"enrollment":2325,"conditions":2345,"interventions":2346},[89],[1122],[2309,2328],{"trials":2348,"activeCount":99},[],{"trials":2350,"activeCount":99},[],{"intervention":2352,"totalTrials":313,"cells":2353},"Weight-based dexamethasone dose",{"EARLY_PHASE1":2354,"PHASE1":2356,"PHASE2":2358,"PHASE3":2360,"PHASE4":2373,"NA":2375},{"trials":2355,"activeCount":99},[],{"trials":2357,"activeCount":99},[],{"trials":2359,"activeCount":99},[],{"trials":2361,"activeCount":99},[2362],{"nctId":2363,"briefTitle":2364,"status":111,"phases":2365,"primaryCompletion":2366,"completion":2367,"start":2368,"enrollment":2369,"conditions":2370,"interventions":2372},"NCT04834375","Randomized Open Investigation Determining Steroid Dose",[89],"2022-01-25","2022-03-29","2021-03-19",142,[2371],"Covid19",[2352],{"trials":2374,"activeCount":99},[],{"trials":2376,"activeCount":99},[],{"intervention":2378,"totalTrials":313,"cells":2379},"Liothyronine",{"EARLY_PHASE1":2380,"PHASE1":2382,"PHASE2":2384,"PHASE3":2386,"PHASE4":2396,"NA":2398},{"trials":2381,"activeCount":99},[],{"trials":2383,"activeCount":99},[],{"trials":2385,"activeCount":99},[],{"trials":2387,"activeCount":99},[2388],{"nctId":2389,"briefTitle":2390,"status":111,"phases":2391,"primaryCompletion":2392,"completion":2392,"start":291,"enrollment":19,"conditions":2393,"interventions":2395},"NCT00790738","Liothyronine (T3) for Bipolar Depression",[89],"2012-07",[2394,24],"Depression",[2378],{"trials":2397,"activeCount":99},[],{"trials":2399,"activeCount":99},[],{"intervention":2401,"totalTrials":313,"cells":2402},"cephalosporins",{"EARLY_PHASE1":2403,"PHASE1":2405,"PHASE2":2407,"PHASE3":2409,"PHASE4":2423,"NA":2425},{"trials":2404,"activeCount":99},[],{"trials":2406,"activeCount":99},[],{"trials":2408,"activeCount":99},[],{"trials":2410,"activeCount":99},[2411],{"nctId":2412,"briefTitle":2413,"status":111,"phases":2414,"primaryCompletion":2415,"completion":1470,"start":2062,"enrollment":2416,"conditions":2417,"interventions":2419},"NCT02579161","Trial of Randomized Antibiotic Administration in Percutaneous Nephrolithotomy",[89],"2018-03",98,[2418],"Kidney Stones",[2401,2420,2421,2422],"Fluoroquinolones","Clindamycin","Ampicillin\u002FGentamicin",{"trials":2424,"activeCount":99},[],{"trials":2426,"activeCount":99},[],{"intervention":2420,"totalTrials":313,"cells":2428},{"EARLY_PHASE1":2429,"PHASE1":2431,"PHASE2":2433,"PHASE3":2435,"PHASE4":2441,"NA":2443},{"trials":2430,"activeCount":99},[],{"trials":2432,"activeCount":99},[],{"trials":2434,"activeCount":99},[],{"trials":2436,"activeCount":99},[2437],{"nctId":2412,"briefTitle":2413,"status":111,"phases":2438,"primaryCompletion":2415,"completion":1470,"start":2062,"enrollment":2416,"conditions":2439,"interventions":2440},[89],[2418],[2401,2420,2421,2422],{"trials":2442,"activeCount":99},[],{"trials":2444,"activeCount":99},[],{"intervention":2421,"totalTrials":313,"cells":2446},{"EARLY_PHASE1":2447,"PHASE1":2449,"PHASE2":2451,"PHASE3":2453,"PHASE4":2459,"NA":2461},{"trials":2448,"activeCount":99},[],{"trials":2450,"activeCount":99},[],{"trials":2452,"activeCount":99},[],{"trials":2454,"activeCount":99},[2455],{"nctId":2412,"briefTitle":2413,"status":111,"phases":2456,"primaryCompletion":2415,"completion":1470,"start":2062,"enrollment":2416,"conditions":2457,"interventions":2458},[89],[2418],[2401,2420,2421,2422],{"trials":2460,"activeCount":99},[],{"trials":2462,"activeCount":99},[],{"intervention":2422,"totalTrials":313,"cells":2464},{"EARLY_PHASE1":2465,"PHASE1":2467,"PHASE2":2469,"PHASE3":2471,"PHASE4":2477,"NA":2479},{"trials":2466,"activeCount":99},[],{"trials":2468,"activeCount":99},[],{"trials":2470,"activeCount":99},[],{"trials":2472,"activeCount":99},[2473],{"nctId":2412,"briefTitle":2413,"status":111,"phases":2474,"primaryCompletion":2415,"completion":1470,"start":2062,"enrollment":2416,"conditions":2475,"interventions":2476},[89],[2418],[2401,2420,2421,2422],{"trials":2478,"activeCount":99},[],{"trials":2480,"activeCount":99},[],{"intervention":636,"totalTrials":313,"cells":2482},{"EARLY_PHASE1":2483,"PHASE1":2485,"PHASE2":2487,"PHASE3":2489,"PHASE4":2495,"NA":2497},{"trials":2484,"activeCount":99},[],{"trials":2486,"activeCount":99},[],{"trials":2488,"activeCount":99},[],{"trials":2490,"activeCount":99},[2491],{"nctId":623,"briefTitle":624,"status":111,"phases":2492,"primaryCompletion":626,"completion":627,"start":149,"enrollment":95,"conditions":2493,"interventions":2494},[89],[629,630,631,632,633,634],[84,636,637],{"trials":2496,"activeCount":99},[],{"trials":2498,"activeCount":99},[],{"intervention":637,"totalTrials":313,"cells":2500},{"EARLY_PHASE1":2501,"PHASE1":2503,"PHASE2":2505,"PHASE3":2507,"PHASE4":2513,"NA":2515},{"trials":2502,"activeCount":99},[],{"trials":2504,"activeCount":99},[],{"trials":2506,"activeCount":99},[],{"trials":2508,"activeCount":99},[2509],{"nctId":623,"briefTitle":624,"status":111,"phases":2510,"primaryCompletion":626,"completion":627,"start":149,"enrollment":95,"conditions":2511,"interventions":2512},[89],[629,630,631,632,633,634],[84,636,637],{"trials":2514,"activeCount":99},[],{"trials":2516,"activeCount":99},[],{"intervention":2518,"totalTrials":180,"cells":2519},"mycophenolate mofetil",{"EARLY_PHASE1":2520,"PHASE1":2522,"PHASE2":2532,"PHASE3":2553,"PHASE4":2555,"NA":2557},{"trials":2521,"activeCount":99},[],{"trials":2523,"activeCount":99},[2524],{"nctId":2525,"briefTitle":2526,"status":111,"phases":2527,"completion":1616,"start":2528,"enrollment":1617,"conditions":2529,"interventions":2531},"NCT00193635","Pilot Study of Mycophenolate Mofetil in Congenital Uropathies",[87],"2002-03",[2530],"Congenital Urological Abnormalities",[2518],{"trials":2533,"activeCount":99},[2534],{"nctId":2535,"briefTitle":2536,"status":111,"phases":2537,"primaryCompletion":2538,"completion":2539,"start":2540,"enrollment":2541,"conditions":2542,"interventions":2545},"NCT02435901","HSCT For Patients With High Risk Hemoglobinopathies Using Reduced Intensity",[87,88],"2019-03","2019-12","2008-12",29,[2543,2544],"Sickle Cell Disease","Beta Thalassemia-Major",[2546,2547,2548,2549,2550,2551,2552],"alemtuzumab","Fludarabine","Melphalan","Cyclosporine","Mycophenolate mofetil","Tacrolimus","Hematopoietic Stem Cell Transplantation",{"trials":2554,"activeCount":99},[],{"trials":2556,"activeCount":99},[],{"trials":2558,"activeCount":99},[],{"intervention":2560,"totalTrials":313,"cells":2561},"Obinutuzumab",{"EARLY_PHASE1":2562,"PHASE1":2564,"PHASE2":2566,"PHASE3":2578,"PHASE4":2580,"NA":2582},{"trials":2563,"activeCount":99},[],{"trials":2565,"activeCount":99},[],{"trials":2567,"activeCount":99},[2568],{"nctId":2569,"briefTitle":2570,"status":258,"phases":2571,"primaryCompletion":2572,"completion":2572,"start":2573,"enrollment":279,"conditions":2574,"interventions":2576},"NCT03145480","Study of Ibrutinib & Obinutuzumab With\u002FWithout CHOP for Richter's Transformation or Richter's Syndrome Patients",[88],"2018-09-28","2017-06-19",[2575],"Richter Syndrome",[2560,2577],"Ibrutinib",{"trials":2579,"activeCount":99},[],{"trials":2581,"activeCount":99},[],{"trials":2583,"activeCount":99},[],{"intervention":2577,"totalTrials":313,"cells":2585},{"EARLY_PHASE1":2586,"PHASE1":2588,"PHASE2":2590,"PHASE3":2596,"PHASE4":2598,"NA":2600},{"trials":2587,"activeCount":99},[],{"trials":2589,"activeCount":99},[],{"trials":2591,"activeCount":99},[2592],{"nctId":2569,"briefTitle":2570,"status":258,"phases":2593,"primaryCompletion":2572,"completion":2572,"start":2573,"enrollment":279,"conditions":2594,"interventions":2595},[88],[2575],[2560,2577],{"trials":2597,"activeCount":99},[],{"trials":2599,"activeCount":99},[],{"trials":2601,"activeCount":99},[],{"intervention":2603,"totalTrials":313,"cells":2604},"Erlotinib",{"EARLY_PHASE1":2605,"PHASE1":2607,"PHASE2":2609,"PHASE3":2618,"PHASE4":2620,"NA":2622},{"trials":2606,"activeCount":99},[],{"trials":2608,"activeCount":99},[],{"trials":2610,"activeCount":99},[2611],{"nctId":2612,"briefTitle":2613,"status":111,"phases":2614,"primaryCompletion":2615,"completion":2615,"start":1769,"enrollment":19,"conditions":2616,"interventions":2617},"NCT00301418","Oral Tarceva Study for Recurrent\u002FResidual Glioblastoma Multiforme and Anaplastic Astrocytoma",[87,88],"2014-05",[18,33],[2603],{"trials":2619,"activeCount":99},[],{"trials":2621,"activeCount":99},[],{"trials":2623,"activeCount":99},[],{"intervention":2625,"totalTrials":313,"cells":2626},"chemotherapy",{"EARLY_PHASE1":2627,"PHASE1":2629,"PHASE2":2631,"PHASE3":2641,"PHASE4":2643,"NA":2645},{"trials":2628,"activeCount":99},[],{"trials":2630,"activeCount":99},[],{"trials":2632,"activeCount":99},[2633],{"nctId":2634,"briefTitle":2635,"status":258,"phases":2636,"primaryCompletion":1615,"completion":1615,"start":2637,"enrollment":180,"conditions":2638,"interventions":2640},"NCT01525927","Study of Chemotherapy Prior to Radiotherapy and Chemotherapy in Patients With HPV Associated Cancer of the Oral Cavity",[88],"2010-08",[2639],"Oropharyngeal Neoplasms",[2625],{"trials":2642,"activeCount":99},[],{"trials":2644,"activeCount":99},[],{"trials":2646,"activeCount":99},[],{"intervention":2648,"totalTrials":313,"cells":2649},"celebrex",{"EARLY_PHASE1":2650,"PHASE1":2652,"PHASE2":2654,"PHASE3":2664,"PHASE4":2666,"NA":2668},{"trials":2651,"activeCount":99},[],{"trials":2653,"activeCount":99},[],{"trials":2655,"activeCount":99},[2656],{"nctId":2657,"briefTitle":2658,"status":111,"phases":2659,"primaryCompletion":331,"completion":331,"start":2660,"enrollment":1929,"conditions":2661,"interventions":2663},"NCT00571701","Study of Celebrex (Celecoxib) in Patients With Recurrent Respiratory Papillomatosis",[88],"2008-02",[2662],"Recurrent Respiratory Papillomatosis",[2648],{"trials":2665,"activeCount":99},[],{"trials":2667,"activeCount":99},[],{"trials":2669,"activeCount":99},[],{"intervention":2671,"totalTrials":313,"cells":2672},"Ketamine Topical",{"EARLY_PHASE1":2673,"PHASE1":2675,"PHASE2":2677,"PHASE3":2691,"PHASE4":2693,"NA":2695},{"trials":2674,"activeCount":99},[],{"trials":2676,"activeCount":99},[],{"trials":2678,"activeCount":99},[2679],{"nctId":2680,"briefTitle":2681,"status":208,"phases":2682,"primaryCompletion":2683,"completion":2684,"start":2685,"enrollment":99,"conditions":2686,"interventions":2690},"NCT05331131","Efficacy of Ketamine Mouthwash in the Management of Oral and Pharyngeal Toxicity Associated With Head and Neck Chemoradiotherapy: A Phase 2, Simon 2-stage Trial",[88],"2025-05-01","2025-11-14","2022-09-19",[2687,2688,2689],"Cancer of Head and Neck","Mucositis Oral","Pharyngeal Mucositis",[2671],{"trials":2692,"activeCount":99},[],{"trials":2694,"activeCount":99},[],{"trials":2696,"activeCount":99},[],{"intervention":2698,"totalTrials":313,"cells":2699},"Naltrexone",{"EARLY_PHASE1":2700,"PHASE1":2702,"PHASE2":2704,"PHASE3":2719,"PHASE4":2721,"NA":2723},{"trials":2701,"activeCount":99},[],{"trials":2703,"activeCount":99},[],{"trials":2705,"activeCount":99},[2706],{"nctId":2707,"briefTitle":2708,"status":111,"phases":2709,"primaryCompletion":2710,"completion":2710,"start":1796,"enrollment":2711,"conditions":2712,"interventions":2718},"NCT02885311","Collaborative Care for Alcohol Use Disorders in the Patient-centered Medical Home",[87,88],"2018-10",27,[2713,2714,2715,2716,2717],"Alcohol-Related Disorders","Alcohol Drinking","Alcoholism","Alcohol Abuse","Alcohol Use Disorders",[2698],{"trials":2720,"activeCount":99},[],{"trials":2722,"activeCount":99},[],{"trials":2724,"activeCount":99},[],{"intervention":2726,"totalTrials":313,"cells":2727},"Probiotic Formulation VSL#3",{"EARLY_PHASE1":2728,"PHASE1":2730,"PHASE2":2732,"PHASE3":2746,"PHASE4":2748,"NA":2750},{"trials":2729,"activeCount":99},[],{"trials":2731,"activeCount":99},[],{"trials":2733,"activeCount":99},[2734],{"nctId":2735,"briefTitle":2736,"status":258,"phases":2737,"primaryCompletion":2738,"completion":2739,"start":2740,"enrollment":227,"conditions":2741,"interventions":2745},"NCT03511365","Effects of Probiotic on Inflammation and Microbiota in Patients With NASH",[87,88],"2018-12-14","2019-10-11","2018-05-15",[2742,2743,2744],"Non-Alcoholic Fatty Liver Disease","Probiotics MeSH Descriptor Data 2018","Interleukin-17 MeSH Descriptor Data 2018",[2726],{"trials":2747,"activeCount":99},[],{"trials":2749,"activeCount":99},[],{"trials":2751,"activeCount":99},[],{"intervention":2753,"totalTrials":313,"cells":2754},"Nelfinavir",{"EARLY_PHASE1":2755,"PHASE1":2757,"PHASE2":2759,"PHASE3":2769,"PHASE4":2771,"NA":2773},{"trials":2756,"activeCount":99},[],{"trials":2758,"activeCount":99},[],{"trials":2760,"activeCount":99},[2761],{"nctId":2762,"briefTitle":2763,"status":258,"phases":2764,"primaryCompletion":2765,"completion":2765,"start":2062,"enrollment":2766,"conditions":2767,"interventions":2768},"NCT02066311","Nelfinavir in Systemic Lupus Erythematosus",[88],"2018-06",15,[744],[2753],{"trials":2770,"activeCount":99},[],{"trials":2772,"activeCount":99},[],{"trials":2774,"activeCount":99},[],{"intervention":2776,"totalTrials":313,"cells":2777},"Topical CBD Patch",{"EARLY_PHASE1":2778,"PHASE1":2780,"PHASE2":2782,"PHASE3":2796,"PHASE4":2798,"NA":2800},{"trials":2779,"activeCount":99},[],{"trials":2781,"activeCount":99},[],{"trials":2783,"activeCount":99},[2784],{"nctId":2785,"briefTitle":2786,"status":208,"phases":2787,"primaryCompletion":2788,"completion":2789,"start":2790,"enrollment":99,"conditions":2791,"interventions":2795},"NCT04412837","The Use of Cannabinoid Patch for Knee Osteoarthritis",[88],"2023-12","2024-02","2022-10",[2792,2793,2794],"Knee Osteoarthritis","CBD","Osteoarthritis",[2776],{"trials":2797,"activeCount":99},[],{"trials":2799,"activeCount":99},[],{"trials":2801,"activeCount":99},[],{"intervention":2803,"totalTrials":313,"cells":2804},"Tranexamic Acid",{"EARLY_PHASE1":2805,"PHASE1":2807,"PHASE2":2809,"PHASE3":2821,"PHASE4":2823,"NA":2825},{"trials":2806,"activeCount":99},[],{"trials":2808,"activeCount":99},[],{"trials":2810,"activeCount":99},[2811],{"nctId":2812,"briefTitle":2813,"status":258,"phases":2814,"primaryCompletion":2815,"completion":2815,"start":2816,"enrollment":306,"conditions":2817,"interventions":2819},"NCT01866943","Role of Topical Tranexamic Acid in Total Hip Arthroplasty",[88],"2016-10","2011-11",[2818],"Post Operative Blood Loss",[2803,2820],"Normal Saline Solution",{"trials":2822,"activeCount":99},[],{"trials":2824,"activeCount":99},[],{"trials":2826,"activeCount":99},[],{"intervention":2820,"totalTrials":313,"cells":2828},{"EARLY_PHASE1":2829,"PHASE1":2831,"PHASE2":2833,"PHASE3":2839,"PHASE4":2841,"NA":2843},{"trials":2830,"activeCount":99},[],{"trials":2832,"activeCount":99},[],{"trials":2834,"activeCount":99},[2835],{"nctId":2812,"briefTitle":2813,"status":258,"phases":2836,"primaryCompletion":2815,"completion":2815,"start":2816,"enrollment":306,"conditions":2837,"interventions":2838},[88],[2818],[2803,2820],{"trials":2840,"activeCount":99},[],{"trials":2842,"activeCount":99},[],{"trials":2844,"activeCount":99},[],{"intervention":2846,"totalTrials":313,"cells":2847},"Niraparib",{"EARLY_PHASE1":2848,"PHASE1":2850,"PHASE2":2852,"PHASE3":2867,"PHASE4":2869,"NA":2871},{"trials":2849,"activeCount":99},[],{"trials":2851,"activeCount":99},[],{"trials":2853,"activeCount":99},[2854],{"nctId":2855,"briefTitle":2856,"status":111,"phases":2857,"primaryCompletion":2858,"completion":2858,"start":2859,"enrollment":1770,"conditions":2860,"interventions":2866},"NCT04080284","Trial of Maintenance With Niraparib- Uterine Serous Carcinoma",[88],"2025-01-01","2019-12-30",[2861,2862,2863,2864,2865],"Endometrial Cancer","Papillary Serous Endometrial Carcinoma","Uterine Serous Carcinoma","Endometrial Carcinoma","Cancer of the Endometrium",[2846],{"trials":2868,"activeCount":99},[],{"trials":2870,"activeCount":99},[],{"trials":2872,"activeCount":99},[],{"intervention":2874,"totalTrials":313,"cells":2875},"Hydroxychloroquine",{"EARLY_PHASE1":2876,"PHASE1":2878,"PHASE2":2880,"PHASE3":2891,"PHASE4":2893,"NA":2895},{"trials":2877,"activeCount":99},[],{"trials":2879,"activeCount":99},[],{"trials":2881,"activeCount":99},[2882],{"nctId":2883,"briefTitle":2884,"status":258,"phases":2885,"primaryCompletion":2886,"completion":2886,"start":291,"enrollment":2887,"conditions":2888,"interventions":2890},"NCT00771056","Hydroxychloroquine in Untreated B-CLL Patients",[88],"2012-01",23,[2889],"B-Cell Chronic Lymphocytic Leukemia",[2874],{"trials":2892,"activeCount":99},[],{"trials":2894,"activeCount":99},[],{"trials":2896,"activeCount":99},[],{"intervention":2898,"totalTrials":313,"cells":2899},"Infusion of Platelets",{"EARLY_PHASE1":2900,"PHASE1":2902,"PHASE2":2904,"PHASE3":2915,"PHASE4":2917,"NA":2919},{"trials":2901,"activeCount":99},[],{"trials":2903,"activeCount":99},[],{"trials":2905,"activeCount":99},[2906],{"nctId":2907,"briefTitle":2908,"status":208,"phases":2909,"primaryCompletion":524,"completion":2910,"start":2911,"enrollment":99,"conditions":2912,"interventions":2914},"NCT03338660","Platelet Function With Various Storage Techniques",[88],"2020-07-15","2018-07-15",[2913],"Platelet Dysfunction Due to Drugs",[2898,2898],{"trials":2916,"activeCount":99},[],{"trials":2918,"activeCount":99},[],{"trials":2920,"activeCount":99},[],{"intervention":2922,"totalTrials":313,"cells":2923},"leucine",{"EARLY_PHASE1":2924,"PHASE1":2926,"PHASE2":2928,"PHASE3":2944,"PHASE4":2946,"NA":2948},{"trials":2925,"activeCount":99},[],{"trials":2927,"activeCount":99},[],{"trials":2929,"activeCount":99},[2930],{"nctId":2931,"briefTitle":2932,"status":111,"phases":2933,"primaryCompletion":2934,"completion":2935,"start":2936,"enrollment":2937,"conditions":2938,"interventions":2943},"NCT01362595","Pilot Phase I\u002FII Study of Amino Acid Leucine in Treatment of Patients With Transfusion-Dependent Diamond Blackfan Anemia",[87,88],"2018-06-30","2020-11-30","2013-06",55,[1238,2939,2940,2941,2942],"Blackfan Diamond Syndrome","DBA","Congenital Hypoplastic Anemia","Pure Red Cell Aplasia",[2922],{"trials":2945,"activeCount":99},[],{"trials":2947,"activeCount":99},[],{"trials":2949,"activeCount":99},[],{"intervention":2546,"totalTrials":313,"cells":2951},{"EARLY_PHASE1":2952,"PHASE1":2954,"PHASE2":2956,"PHASE3":2962,"PHASE4":2964,"NA":2966},{"trials":2953,"activeCount":99},[],{"trials":2955,"activeCount":99},[],{"trials":2957,"activeCount":99},[2958],{"nctId":2535,"briefTitle":2536,"status":111,"phases":2959,"primaryCompletion":2538,"completion":2539,"start":2540,"enrollment":2541,"conditions":2960,"interventions":2961},[87,88],[2543,2544],[2546,2547,2548,2549,2550,2551,2552],{"trials":2963,"activeCount":99},[],{"trials":2965,"activeCount":99},[],{"trials":2967,"activeCount":99},[],{"intervention":2547,"totalTrials":313,"cells":2969},{"EARLY_PHASE1":2970,"PHASE1":2972,"PHASE2":2974,"PHASE3":2980,"PHASE4":2982,"NA":2984},{"trials":2971,"activeCount":99},[],{"trials":2973,"activeCount":99},[],{"trials":2975,"activeCount":99},[2976],{"nctId":2535,"briefTitle":2536,"status":111,"phases":2977,"primaryCompletion":2538,"completion":2539,"start":2540,"enrollment":2541,"conditions":2978,"interventions":2979},[87,88],[2543,2544],[2546,2547,2548,2549,2550,2551,2552],{"trials":2981,"activeCount":99},[],{"trials":2983,"activeCount":99},[],{"trials":2985,"activeCount":99},[],{"intervention":2548,"totalTrials":313,"cells":2987},{"EARLY_PHASE1":2988,"PHASE1":2990,"PHASE2":2992,"PHASE3":2998,"PHASE4":3000,"NA":3002},{"trials":2989,"activeCount":99},[],{"trials":2991,"activeCount":99},[],{"trials":2993,"activeCount":99},[2994],{"nctId":2535,"briefTitle":2536,"status":111,"phases":2995,"primaryCompletion":2538,"completion":2539,"start":2540,"enrollment":2541,"conditions":2996,"interventions":2997},[87,88],[2543,2544],[2546,2547,2548,2549,2550,2551,2552],{"trials":2999,"activeCount":99},[],{"trials":3001,"activeCount":99},[],{"trials":3003,"activeCount":99},[],{"intervention":2549,"totalTrials":313,"cells":3005},{"EARLY_PHASE1":3006,"PHASE1":3008,"PHASE2":3010,"PHASE3":3016,"PHASE4":3018,"NA":3020},{"trials":3007,"activeCount":99},[],{"trials":3009,"activeCount":99},[],{"trials":3011,"activeCount":99},[3012],{"nctId":2535,"briefTitle":2536,"status":111,"phases":3013,"primaryCompletion":2538,"completion":2539,"start":2540,"enrollment":2541,"conditions":3014,"interventions":3015},[87,88],[2543,2544],[2546,2547,2548,2549,2550,2551,2552],{"trials":3017,"activeCount":99},[],{"trials":3019,"activeCount":99},[],{"trials":3021,"activeCount":99},[],{"intervention":2551,"totalTrials":313,"cells":3023},{"EARLY_PHASE1":3024,"PHASE1":3026,"PHASE2":3028,"PHASE3":3034,"PHASE4":3036,"NA":3038},{"trials":3025,"activeCount":99},[],{"trials":3027,"activeCount":99},[],{"trials":3029,"activeCount":99},[3030],{"nctId":2535,"briefTitle":2536,"status":111,"phases":3031,"primaryCompletion":2538,"completion":2539,"start":2540,"enrollment":2541,"conditions":3032,"interventions":3033},[87,88],[2543,2544],[2546,2547,2548,2549,2550,2551,2552],{"trials":3035,"activeCount":99},[],{"trials":3037,"activeCount":99},[],{"trials":3039,"activeCount":99},[],{"intervention":2552,"totalTrials":313,"cells":3041},{"EARLY_PHASE1":3042,"PHASE1":3044,"PHASE2":3046,"PHASE3":3052,"PHASE4":3054,"NA":3056},{"trials":3043,"activeCount":99},[],{"trials":3045,"activeCount":99},[],{"trials":3047,"activeCount":99},[3048],{"nctId":2535,"briefTitle":2536,"status":111,"phases":3049,"primaryCompletion":2538,"completion":2539,"start":2540,"enrollment":2541,"conditions":3050,"interventions":3051},[87,88],[2543,2544],[2546,2547,2548,2549,2550,2551,2552],{"trials":3053,"activeCount":99},[],{"trials":3055,"activeCount":99},[],{"trials":3057,"activeCount":99},[],{"intervention":3059,"totalTrials":313,"cells":3060},"Sotatercept",{"EARLY_PHASE1":3061,"PHASE1":3063,"PHASE2":3065,"PHASE3":3076,"PHASE4":3078,"NA":3080},{"trials":3062,"activeCount":99},[],{"trials":3064,"activeCount":99},[],{"trials":3066,"activeCount":99},[3067],{"nctId":3068,"briefTitle":3069,"status":258,"phases":3070,"primaryCompletion":3071,"completion":3071,"start":2886,"enrollment":3072,"conditions":3073,"interventions":3074},"NCT01464164","Safety and Efficacy Study of Sotatercept in Adults With Transfusion Dependent Diamond Blackfan Anemia",[87,88],"2021-04-13",19,[1238],[3059,3075],"Sotatercept with prednisone boost",{"trials":3077,"activeCount":99},[],{"trials":3079,"activeCount":99},[],{"trials":3081,"activeCount":99},[],{"intervention":3075,"totalTrials":313,"cells":3083},{"EARLY_PHASE1":3084,"PHASE1":3086,"PHASE2":3088,"PHASE3":3094,"PHASE4":3096,"NA":3098},{"trials":3085,"activeCount":99},[],{"trials":3087,"activeCount":99},[],{"trials":3089,"activeCount":99},[3090],{"nctId":3068,"briefTitle":3069,"status":258,"phases":3091,"primaryCompletion":3071,"completion":3071,"start":2886,"enrollment":3072,"conditions":3092,"interventions":3093},[87,88],[1238],[3059,3075],{"trials":3095,"activeCount":99},[],{"trials":3097,"activeCount":99},[],{"trials":3099,"activeCount":99},[],{"intervention":3101,"totalTrials":313,"cells":3102},"Paclitaxel\u002FCarboplatin",{"EARLY_PHASE1":3103,"PHASE1":3105,"PHASE2":3107,"PHASE3":3119,"PHASE4":3121,"NA":3123},{"trials":3104,"activeCount":99},[],{"trials":3106,"activeCount":99},[],{"trials":3108,"activeCount":99},[3109],{"nctId":3110,"briefTitle":3111,"status":208,"phases":3112,"primaryCompletion":3113,"completion":3114,"start":3115,"enrollment":99,"conditions":3116,"interventions":3118},"NCT04030000","Uterine Serous Carcinoma and Adjuvant Combined Intraperitoneal Chemotherapy and Radiation",[87,88],"2022-08-30","2023-01-30","2020-05-20",[3117],"Uterine Carcinoma",[3101],{"trials":3120,"activeCount":99},[],{"trials":3122,"activeCount":99},[],{"trials":3124,"activeCount":99},[],{"intervention":3126,"totalTrials":313,"cells":3127},"rhDNAse",{"EARLY_PHASE1":3128,"PHASE1":3130,"PHASE2":3132,"PHASE3":3142,"PHASE4":3144,"NA":3146},{"trials":3129,"activeCount":99},[],{"trials":3131,"activeCount":99},[],{"trials":3133,"activeCount":99},[3134],{"nctId":3135,"briefTitle":3136,"status":111,"phases":3137,"primaryCompletion":3138,"completion":3138,"start":272,"enrollment":3139,"conditions":3140,"interventions":3141},"NCT00169962","Study of Pulmozyme to Treat Severe Asthma Episodes",[88],"2006-09",51,[2173],[3126],{"trials":3143,"activeCount":99},[],{"trials":3145,"activeCount":99},[],{"trials":3147,"activeCount":99},[],{"intervention":3149,"totalTrials":313,"cells":3150},"Estradiol",{"EARLY_PHASE1":3151,"PHASE1":3153,"PHASE2":3155,"PHASE3":3168,"PHASE4":3170,"NA":3172},{"trials":3152,"activeCount":99},[],{"trials":3154,"activeCount":99},[],{"trials":3156,"activeCount":99},[3157],{"nctId":3158,"briefTitle":3159,"status":208,"phases":3160,"primaryCompletion":3161,"completion":3161,"start":3162,"enrollment":99,"conditions":3163,"interventions":3167},"NCT02316249","Vaginal Creams to Reduce Vaginal Erosion in Pessary Users",[88],"2015-08","2015-04",[3164,3165,3166],"Atrophy of Vagina","Vaginal Ulceration","Vaginitis",[3149],{"trials":3169,"activeCount":99},[],{"trials":3171,"activeCount":99},[],{"trials":3173,"activeCount":99},[],{"intervention":3175,"totalTrials":313,"cells":3176},"Sodium Bicarbonate",{"EARLY_PHASE1":3177,"PHASE1":3179,"PHASE2":3181,"PHASE3":3195,"PHASE4":3197,"NA":3199},{"trials":3178,"activeCount":99},[],{"trials":3180,"activeCount":99},[],{"trials":3182,"activeCount":99},[3183],{"nctId":3184,"briefTitle":3185,"status":258,"phases":3186,"primaryCompletion":3187,"completion":3188,"start":3189,"enrollment":3139,"conditions":3190,"interventions":3193},"NCT02046135","Sodium Bicarbonate to Prevent Acute Kidney Injury in Children Undergoing Cardiac Surgery",[88],"2017-06","2017-07-22","2013-09",[3191,3192],"Acute Kidney Injury","Congenital Heart Disease",[3175,3194],"Sodium Chloride",{"trials":3196,"activeCount":99},[],{"trials":3198,"activeCount":99},[],{"trials":3200,"activeCount":99},[],{"intervention":3194,"totalTrials":313,"cells":3202},{"EARLY_PHASE1":3203,"PHASE1":3205,"PHASE2":3207,"PHASE3":3213,"PHASE4":3215,"NA":3217},{"trials":3204,"activeCount":99},[],{"trials":3206,"activeCount":99},[],{"trials":3208,"activeCount":99},[3209],{"nctId":3184,"briefTitle":3185,"status":258,"phases":3210,"primaryCompletion":3187,"completion":3188,"start":3189,"enrollment":3139,"conditions":3211,"interventions":3212},[88],[3191,3192],[3175,3194],{"trials":3214,"activeCount":99},[],{"trials":3216,"activeCount":99},[],{"trials":3218,"activeCount":99},[],{"intervention":3220,"totalTrials":313,"cells":3221},"Bevacizumab and Carboplatin",{"EARLY_PHASE1":3222,"PHASE1":3224,"PHASE2":3226,"PHASE3":3235,"PHASE4":3237,"NA":3239},{"trials":3223,"activeCount":99},[],{"trials":3225,"activeCount":99},[],{"trials":3227,"activeCount":99},[3228],{"nctId":3229,"briefTitle":3230,"status":652,"phases":3231,"primaryCompletion":3232,"completion":3232,"start":2063,"enrollment":677,"conditions":3233,"interventions":3234},"NCT01386710","Repeated Super-selective Intraarterial Cerebral Infusion Of Bevacizumab Plus Carboplatin For Treatment Of Relapsed\u002FRefractory GBM And Anaplastic Astrocytoma",[87,88],"2027-12",[18,33],[3220,3220],{"trials":3236,"activeCount":99},[],{"trials":3238,"activeCount":99},[],{"trials":3240,"activeCount":99},[],{"intervention":3242,"totalTrials":313,"cells":3243},"Furosemide",{"EARLY_PHASE1":3244,"PHASE1":3246,"PHASE2":3248,"PHASE3":3260,"PHASE4":3262,"NA":3264},{"trials":3245,"activeCount":99},[],{"trials":3247,"activeCount":99},[],{"trials":3249,"activeCount":99},[3250],{"nctId":3251,"briefTitle":3252,"status":111,"phases":3253,"primaryCompletion":3254,"completion":3254,"start":3255,"enrollment":3256,"conditions":3257,"interventions":3259},"NCT02469597","Single Dose of Furosemide to Improve Respiratory Distress in Moderate to Severe Bronchiolitis",[88],"2016-04","2013-10",46,[3258],"Bronchiolitis",[3242],{"trials":3261,"activeCount":99},[],{"trials":3263,"activeCount":99},[],{"trials":3265,"activeCount":99},[],{"intervention":3267,"totalTrials":313,"cells":3268},"Heliox",{"EARLY_PHASE1":3269,"PHASE1":3271,"PHASE2":3273,"PHASE3":3282,"PHASE4":3284,"NA":3286},{"trials":3270,"activeCount":99},[],{"trials":3272,"activeCount":99},[],{"trials":3274,"activeCount":99},[3275],{"nctId":3276,"briefTitle":3277,"status":111,"phases":3278,"primaryCompletion":1927,"completion":1927,"start":2169,"enrollment":1281,"conditions":3279,"interventions":3281},"NCT02135900","The Use of Heliox in Obstructive Sleep Apnea Syndrome",[88],[3280],"Obstructive Sleep Apnea Syndrome",[3267],{"trials":3283,"activeCount":99},[],{"trials":3285,"activeCount":99},[],{"trials":3287,"activeCount":99},[],{"intervention":3289,"totalTrials":313,"cells":3290},"Lanreotide",{"EARLY_PHASE1":3291,"PHASE1":3293,"PHASE2":3295,"PHASE3":3308,"PHASE4":3310,"NA":3312},{"trials":3292,"activeCount":99},[],{"trials":3294,"activeCount":99},[],{"trials":3296,"activeCount":99},[3297],{"nctId":3298,"briefTitle":3299,"status":111,"phases":3300,"primaryCompletion":3301,"completion":3302,"start":3303,"enrollment":1617,"conditions":3304,"interventions":3307},"NCT03012594","Lanreotide in the Treatment of Small Bowel Motility Disorders",[88],"2018-10-21","2019-03-11","2017-05-11",[3305,3306],"Gastrointestinal Motility Disorder","Intestinal Disease",[3289],{"trials":3309,"activeCount":99},[],{"trials":3311,"activeCount":99},[],{"trials":3313,"activeCount":99},[],{"intervention":3315,"totalTrials":180,"cells":3316},"Galactose",{"EARLY_PHASE1":3317,"PHASE1":3319,"PHASE2":3334,"PHASE3":3336,"PHASE4":3338,"NA":3340},{"trials":3318,"activeCount":99},[],{"trials":3320,"activeCount":99},[3321,3328],{"nctId":3322,"briefTitle":3323,"status":208,"phases":3324,"primaryCompletion":2169,"completion":2169,"start":2540,"enrollment":99,"conditions":3325,"interventions":3327},"NCT00816504","Effect of Galactose on Permeblity Factor in Patients With FSGS and CKD Stage 5",[87],[3326],"Focal Segmental Glomerulosclerosis",[3315],{"nctId":3329,"briefTitle":3330,"status":258,"phases":3331,"primaryCompletion":2169,"completion":2169,"start":2540,"enrollment":2766,"conditions":3332,"interventions":3333},"NCT00816478","Effect of Oral Galactose on Focal Segmental Glomerulosclerosis (FSGS) Permeability Factor",[87],[3326],[3315],{"trials":3335,"activeCount":99},[],{"trials":3337,"activeCount":99},[],{"trials":3339,"activeCount":99},[],{"trials":3341,"activeCount":99},[],{"intervention":3343,"totalTrials":313,"cells":3344},"Epidiolex 100 mg\u002FmL Oral Solution",{"EARLY_PHASE1":3345,"PHASE1":3347,"PHASE2":3359,"PHASE3":3361,"PHASE4":3363,"NA":3365},{"trials":3346,"activeCount":99},[],{"trials":3348,"activeCount":99},[3349],{"nctId":3350,"briefTitle":3351,"status":111,"phases":3352,"primaryCompletion":3353,"completion":3353,"start":3354,"enrollment":3355,"conditions":3356,"interventions":3358},"NCT04721691","Efficacy of Epidiolex in Patients With Electrical Status Epilepticus of Sleep (ESES).",[87],"2024-01-17","2021-03-10",16,[3357],"Electrical Status Epilepticus of Slow-Wave Sleep",[3343],{"trials":3360,"activeCount":99},[],{"trials":3362,"activeCount":99},[],{"trials":3364,"activeCount":99},[],{"trials":3366,"activeCount":99},[],{"intervention":3368,"totalTrials":313,"cells":3369},"Cisplatin",{"EARLY_PHASE1":3370,"PHASE1":3372,"PHASE2":3386,"PHASE3":3388,"PHASE4":3390,"NA":3392},{"trials":3371,"activeCount":99},[],{"trials":3373,"activeCount":99},[3374],{"nctId":3375,"briefTitle":3376,"status":1688,"phases":3377,"primaryCompletion":3378,"completion":3379,"start":3380,"enrollment":2766,"conditions":3381,"interventions":3385},"NCT03540017","HIPEC After Initial CRS in Patients Who Have Received NACT",[87],"2024-07-05","2025-07-05","2019-03-12",[3382,3383,3384],"Ovarian Cancer","Fallopian Tube Cancer","Primary Peritoneal Carcinoma",[3368],{"trials":3387,"activeCount":99},[],{"trials":3389,"activeCount":99},[],{"trials":3391,"activeCount":99},[],{"trials":3393,"activeCount":99},[],{"intervention":3395,"totalTrials":313,"cells":3396},"MSI-1436C",{"EARLY_PHASE1":3397,"PHASE1":3399,"PHASE2":3409,"PHASE3":3411,"PHASE4":3413,"NA":3415},{"trials":3398,"activeCount":99},[],{"trials":3400,"activeCount":99},[3401],{"nctId":3402,"briefTitle":3403,"status":258,"phases":3404,"primaryCompletion":1839,"completion":3405,"start":3254,"enrollment":1286,"conditions":3406,"interventions":3408},"NCT02524951","Safety and Tolerability of MSI-1436C in Metastatic Breast Cancer",[87],"2018-05-14",[3407],"Metastatic Breast Cancer",[3395],{"trials":3410,"activeCount":99},[],{"trials":3412,"activeCount":99},[],{"trials":3414,"activeCount":99},[],{"trials":3416,"activeCount":99},[],{"intervention":3418,"totalTrials":313,"cells":3419},"Superselective Intraarterial Cerebral Infusion of Cetuximab",{"EARLY_PHASE1":3420,"PHASE1":3422,"PHASE2":3432,"PHASE3":3434,"PHASE4":3436,"NA":3438},{"trials":3421,"activeCount":99},[],{"trials":3423,"activeCount":99},[3424],{"nctId":3425,"briefTitle":3426,"status":111,"phases":3427,"primaryCompletion":3428,"completion":3428,"start":2169,"enrollment":2766,"conditions":3429,"interventions":3431},"NCT01238237","Super-Selective Intraarterial Cerebral Infusion of Cetuximab (Erbitux) for Treatment of Relapsed\u002FRefractory GBM and AA",[87],"2016-01",[815,3430,484,33],"ANAPLASTIC ASTROCYTOMA (AOA)",[3418],{"trials":3433,"activeCount":99},[],{"trials":3435,"activeCount":99},[],{"trials":3437,"activeCount":99},[],{"trials":3439,"activeCount":99},[],{"intervention":3441,"totalTrials":313,"cells":3442},"BR-DIM",{"EARLY_PHASE1":3443,"PHASE1":3445,"PHASE2":3454,"PHASE3":3456,"PHASE4":3458,"NA":3460},{"trials":3444,"activeCount":99},[],{"trials":3446,"activeCount":99},[3447],{"nctId":3448,"briefTitle":3449,"status":258,"phases":3450,"primaryCompletion":3428,"completion":3428,"start":3428,"enrollment":227,"conditions":3451,"interventions":3453},"NCT02483624","3,3'-Diindolylmethane in Patients With Systemic Lupus Erythematosus",[87],[3452],"SLE",[3441],{"trials":3455,"activeCount":99},[],{"trials":3457,"activeCount":99},[],{"trials":3459,"activeCount":99},[],{"trials":3461,"activeCount":99},[],{"intervention":3463,"totalTrials":313,"cells":3464},"Intraarterial Cetxuimab",{"EARLY_PHASE1":3465,"PHASE1":3467,"PHASE2":3479,"PHASE3":3481,"PHASE4":3483,"NA":3485},{"trials":3466,"activeCount":99},[],{"trials":3468,"activeCount":99},[3469],{"nctId":3470,"briefTitle":3471,"status":258,"phases":3472,"primaryCompletion":3473,"completion":3473,"start":3474,"enrollment":19,"conditions":3475,"interventions":3478},"NCT02438995","Super-Selective Intraarterial Infusion of Cetuximab (Erbitux) With or Without Radiation Therapy for the Treatment of Unresectable Recurrent Squamous Cell Carcinoma of the Head and Neck",[87],"2021-06","2015-05",[3476,3477],"Carcinoma, Squamous Cell","Carcinoma, Squamous Cell of Head and Neck",[3463],{"trials":3480,"activeCount":99},[],{"trials":3482,"activeCount":99},[],{"trials":3484,"activeCount":99},[],{"trials":3486,"activeCount":99},[],{"intervention":3488,"totalTrials":313,"cells":3489},"Triiodothyronine",{"EARLY_PHASE1":3490,"PHASE1":3492,"PHASE2":3505,"PHASE3":3507,"PHASE4":3509,"NA":3511},{"trials":3491,"activeCount":99},[],{"trials":3493,"activeCount":99},[3494],{"nctId":3495,"briefTitle":3496,"status":111,"phases":3497,"primaryCompletion":113,"completion":3498,"start":3499,"enrollment":3500,"conditions":3501,"interventions":3503},"NCT00289367","Study of T3 on the Incidence of Atrial Fibrillation in Patients Undergoing Cardiac Surgery",[87],"2008-05","2006-02",280,[3502],"Atrial Fibrillation",[3488,3504],"triiodothyronine",{"trials":3506,"activeCount":99},[],{"trials":3508,"activeCount":99},[],{"trials":3510,"activeCount":99},[],{"trials":3512,"activeCount":99},[],{"intervention":3514,"totalTrials":313,"cells":3515},"Rosiglitazone",{"EARLY_PHASE1":3516,"PHASE1":3518,"PHASE2":3530,"PHASE3":3532,"PHASE4":3534,"NA":3536},{"trials":3517,"activeCount":99},[],{"trials":3519,"activeCount":99},[3520],{"nctId":3521,"briefTitle":3522,"status":111,"phases":3523,"completion":3524,"start":3525,"enrollment":16,"conditions":3526,"interventions":3528},"NCT00193648","Pilot Studies of Novel Therapies to Treat Resistant Focal Segmental Glomerulosclerosis (FSGS)",[87],"2007-10","2005-07",[3527],"Focal Glomerulosclerosis",[3514,3529],"Adalimumab",{"trials":3531,"activeCount":99},[],{"trials":3533,"activeCount":99},[],{"trials":3535,"activeCount":99},[],{"trials":3537,"activeCount":99},[],{"intervention":3529,"totalTrials":313,"cells":3539},{"EARLY_PHASE1":3540,"PHASE1":3542,"PHASE2":3548,"PHASE3":3550,"PHASE4":3552,"NA":3554},{"trials":3541,"activeCount":99},[],{"trials":3543,"activeCount":99},[3544],{"nctId":3521,"briefTitle":3522,"status":111,"phases":3545,"completion":3524,"start":3525,"enrollment":16,"conditions":3546,"interventions":3547},[87],[3527],[3514,3529],{"trials":3549,"activeCount":99},[],{"trials":3551,"activeCount":99},[],{"trials":3553,"activeCount":99},[],{"trials":3555,"activeCount":99},[],{"intervention":3557,"totalTrials":313,"cells":3558},"Super-Selective Intraarterial Intracranial Infusion of Temozolomide",{"EARLY_PHASE1":3559,"PHASE1":3561,"PHASE2":3571,"PHASE3":3573,"PHASE4":3575,"NA":3577},{"trials":3560,"activeCount":99},[],{"trials":3562,"activeCount":99},[3563],{"nctId":3564,"briefTitle":3565,"status":111,"phases":3566,"primaryCompletion":3567,"completion":3568,"start":2637,"enrollment":16,"conditions":3569,"interventions":3570},"NCT01180816","Super-Selective Intraarterial Cerebral Infusion Of Temozolomide (Temodar) For Treatment Of Newly Diagnosed GBM And AA",[87],"2017-12","2020-08-11",[18,33],[3557],{"trials":3572,"activeCount":99},[],{"trials":3574,"activeCount":99},[],{"trials":3576,"activeCount":99},[],{"trials":3578,"activeCount":99},[],{"intervention":3580,"totalTrials":313,"cells":3581},"Super-Selective Intraarterial Intracranial Infusion of BEVACIZUMAB",{"EARLY_PHASE1":3582,"PHASE1":3584,"PHASE2":3594,"PHASE3":3596,"PHASE4":3598,"NA":3600},{"trials":3583,"activeCount":99},[],{"trials":3585,"activeCount":99},[3586],{"nctId":3587,"briefTitle":3588,"status":111,"phases":3589,"primaryCompletion":3590,"completion":3590,"start":3591,"enrollment":273,"conditions":3592,"interventions":3593},"NCT00968240","Super-Selective Intraarterial Intracranial Infusion of Avastin (Bevacizumab)",[87],"2014-01","2009-07",[18,33],[3580],{"trials":3595,"activeCount":99},[],{"trials":3597,"activeCount":99},[],{"trials":3599,"activeCount":99},[],{"trials":3601,"activeCount":99},[],{"intervention":3603,"totalTrials":313,"cells":3604},"Intra-arterial cold saline, minocycline, and magnesium",{"EARLY_PHASE1":3605,"PHASE1":3607,"PHASE2":3619,"PHASE3":3621,"PHASE4":3623,"NA":3625},{"trials":3606,"activeCount":99},[],{"trials":3608,"activeCount":99},[3609],{"nctId":3610,"briefTitle":3611,"status":208,"phases":3612,"primaryCompletion":3613,"completion":3614,"start":3615,"enrollment":99,"conditions":3616,"interventions":3618},"NCT05032781","Intra-Arterial Neuroprotective Agents and Cold Saline in Ischemic Stroke Intervention",[87],"2024-09","2026-03","2021-06-01",[3617],"Stroke, Ischemic",[3603],{"trials":3620,"activeCount":99},[],{"trials":3622,"activeCount":99},[],{"trials":3624,"activeCount":99},[],{"trials":3626,"activeCount":99},[],{"intervention":3628,"totalTrials":313,"cells":3629},"Intra-arterial Cerebral Infusion of Trastuzumab",{"EARLY_PHASE1":3630,"PHASE1":3632,"PHASE2":3641,"PHASE3":3643,"PHASE4":3645,"NA":3647},{"trials":3631,"activeCount":99},[],{"trials":3633,"activeCount":99},[3634],{"nctId":3635,"briefTitle":3636,"status":258,"phases":3637,"primaryCompletion":3473,"completion":3473,"start":3161,"enrollment":180,"conditions":3638,"interventions":3640},"NCT02571530","Super-selective Intra-arterial Cerebral Infusion of Trastuzumab for the Treatment of Cerebral Metastases of HER2\u002FNeu Positive Breast Cancer",[87],[3639],"Neoplasm Metastasis",[3628],{"trials":3642,"activeCount":99},[],{"trials":3644,"activeCount":99},[],{"trials":3646,"activeCount":99},[],{"trials":3648,"activeCount":99},[],{"intervention":3650,"totalTrials":313,"cells":3651},"Casirivimab and Imdevimab Antibody Cocktail",{"EARLY_PHASE1":3652,"PHASE1":3654,"PHASE2":3666,"PHASE3":3668,"PHASE4":3670,"NA":3672},{"trials":3653,"activeCount":99},[],{"trials":3655,"activeCount":99},[3656],{"nctId":3657,"briefTitle":3658,"status":208,"phases":3659,"primaryCompletion":3660,"completion":3661,"start":3662,"enrollment":99,"conditions":3663,"interventions":3665},"NCT05157997","Transplantation of Deceased Donors With COVID-19 Into COVID-19 Negative Recipients Utilizing Casirivimab and Imdevimab Antibody Cocktail",[87],"2024-01","2025-01","2022-01",[1122,3664],"Organ Transplant",[3650],{"trials":3667,"activeCount":99},[],{"trials":3669,"activeCount":99},[],{"trials":3671,"activeCount":99},[],{"trials":3673,"activeCount":99},[],{"intervention":3675,"totalTrials":313,"cells":3676},"Metformin",{"EARLY_PHASE1":3677,"PHASE1":3679,"PHASE2":3689,"PHASE3":3691,"PHASE4":3693,"NA":3695},{"trials":3678,"activeCount":99},[],{"trials":3680,"activeCount":99},[3681],{"nctId":3682,"briefTitle":3683,"status":208,"phases":3684,"primaryCompletion":1839,"completion":1839,"start":3685,"enrollment":99,"conditions":3686,"interventions":3688},"NCT02457286","Improving Insulin Resistance To Treat Non-Alcoholic Fatty Liver Disease: A Pilot Study",[87],"2015-06",[3687],"Non-alcoholic Fatty Liver Disease (NAFLD)",[3675],{"trials":3690,"activeCount":99},[],{"trials":3692,"activeCount":99},[],{"trials":3694,"activeCount":99},[],{"trials":3696,"activeCount":99},[],{"intervention":3698,"totalTrials":313,"cells":3699},"onabotulinumtoxin A",{"EARLY_PHASE1":3700,"PHASE1":3710,"PHASE2":3712,"PHASE3":3714,"PHASE4":3716,"NA":3718},{"trials":3701,"activeCount":99},[3702],{"nctId":3703,"briefTitle":3704,"status":652,"phases":3705,"primaryCompletion":339,"completion":3706,"start":627,"enrollment":1320,"conditions":3707,"interventions":3709},"NCT04984317","Feasibility of BOTOX Injection on Improving Female Stress Urinary Incontinence",[86],"2027-08",[3708],"Stress Urinary Incontinence",[3698],{"trials":3711,"activeCount":99},[],{"trials":3713,"activeCount":99},[],{"trials":3715,"activeCount":99},[],{"trials":3717,"activeCount":99},[],{"trials":3719,"activeCount":99},[],{"intervention":3721,"totalTrials":313,"cells":3722},"Dexamethasone",{"EARLY_PHASE1":3723,"PHASE1":3734,"PHASE2":3736,"PHASE3":3738,"PHASE4":3740,"NA":3742},{"trials":3724,"activeCount":99},[3725],{"nctId":3726,"briefTitle":3727,"status":111,"phases":3728,"primaryCompletion":3729,"completion":1883,"start":3730,"enrollment":408,"conditions":3731,"interventions":3733},"NCT04889547","Randomized Controlled Trial Assessing the Effect of Dexamethasone on Postoperative Function After Distal Radius Fixation",[86],"2023-07-01","2021-07-10",[3732],"Distal Radius Fracture",[3721],{"trials":3735,"activeCount":99},[],{"trials":3737,"activeCount":99},[],{"trials":3739,"activeCount":99},[],{"trials":3741,"activeCount":99},[],{"trials":3743,"activeCount":99},[],{"intervention":3745,"totalTrials":313,"cells":3746},"Lidocaine induced basivertebral nerve block",{"EARLY_PHASE1":3747,"PHASE1":3761,"PHASE2":3763,"PHASE3":3765,"PHASE4":3767,"NA":3769},{"trials":3748,"activeCount":99},[3749],{"nctId":3750,"briefTitle":3751,"status":111,"phases":3752,"primaryCompletion":3753,"completion":3754,"start":3755,"enrollment":95,"conditions":3756,"interventions":3760},"NCT04774029","Basivertebral Nerve Block During Vertebral Augmentation: An Alternative Approach to Intraprocedural Pain Management",[86],"2020-04-01","2020-05-01","2020-01-10",[3757,3758,3759],"Vertebral Compression","Vertebra Compression Fracture","Vertebral Fracture",[3745],{"trials":3762,"activeCount":99},[],{"trials":3764,"activeCount":99},[],{"trials":3766,"activeCount":99},[],{"trials":3768,"activeCount":99},[],{"trials":3770,"activeCount":99},[],{"intervention":3772,"totalTrials":313,"cells":3773},"Ketamine 100 MG\u002FML",{"EARLY_PHASE1":3774,"PHASE1":3787,"PHASE2":3789,"PHASE3":3791,"PHASE4":3793,"NA":3795},{"trials":3775,"activeCount":99},[3776],{"nctId":3777,"briefTitle":3778,"status":208,"phases":3779,"primaryCompletion":3780,"completion":3780,"start":3781,"enrollment":99,"conditions":3782,"interventions":3786},"NCT05344625","Ketamine-Assisted PsychoTherapy ViAbility in Treating Cancer-related Emotional Distress",[86],"2024-03-15","2023-10-31",[3783,3784,3785],"Cancer-related Problem\u002FCondition","Depressive Symptoms","Anxiety Disorders",[3772],{"trials":3788,"activeCount":99},[],{"trials":3790,"activeCount":99},[],{"trials":3792,"activeCount":99},[],{"trials":3794,"activeCount":99},[],{"trials":3796,"activeCount":99},[],{"intervention":3798,"totalTrials":313,"cells":3799},"Insulin",{"EARLY_PHASE1":3800,"PHASE1":3812,"PHASE2":3814,"PHASE3":3816,"PHASE4":3818,"NA":3820},{"trials":3801,"activeCount":99},[3802],{"nctId":3803,"briefTitle":3804,"status":111,"phases":3805,"primaryCompletion":3806,"completion":3807,"start":3808,"enrollment":115,"conditions":3809,"interventions":3811},"NCT04742023","Post-operative Complications and Graft Survival With Conventional Versus Continuous Glucose Monitoring in Patients With Diabetes Mellitus Undergoing Renal Transplantation",[86],"2023-11-21","2023-12-21","2020-04-21",[3810],"Diabetes Mellitus",[3798],{"trials":3813,"activeCount":99},[],{"trials":3815,"activeCount":99},[],{"trials":3817,"activeCount":99},[],{"trials":3819,"activeCount":99},[],{"trials":3821,"activeCount":99},[],{"intervention":3823,"totalTrials":313,"cells":3824},"Lorazepam 1Mg",{"EARLY_PHASE1":3825,"PHASE1":3836,"PHASE2":3838,"PHASE3":3840,"PHASE4":3842,"NA":3844},{"trials":3826,"activeCount":99},[3827],{"nctId":3828,"briefTitle":3829,"status":208,"phases":3830,"primaryCompletion":3831,"completion":3831,"start":3662,"enrollment":99,"conditions":3832,"interventions":3835},"NCT04671836","Lorazepam Effects on Neuroimaging Measures",[86],"2022-12",[3833,3834],"Lorazepam","Neuroimaging",[3823],{"trials":3837,"activeCount":99},[],{"trials":3839,"activeCount":99},[],{"trials":3841,"activeCount":99},[],{"trials":3843,"activeCount":99},[],{"trials":3845,"activeCount":99},[],{"intervention":3847,"totalTrials":313,"cells":3848},"Dobutamine",{"EARLY_PHASE1":3849,"PHASE1":3860,"PHASE2":3862,"PHASE3":3864,"PHASE4":3866,"NA":3868},{"trials":3850,"activeCount":99},[3851],{"nctId":3852,"briefTitle":3853,"status":111,"phases":3854,"primaryCompletion":3855,"completion":3855,"start":3856,"enrollment":553,"conditions":3857,"interventions":3859},"NCT04249258","Dobutamine on the Cardiac Conduction System",[86],"2021-11-20","2020-01-14",[3858],"Arrhythmias, Cardiac",[3847],{"trials":3861,"activeCount":99},[],{"trials":3863,"activeCount":99},[],{"trials":3865,"activeCount":99},[],{"trials":3867,"activeCount":99},[],{"trials":3869,"activeCount":99},[],{"intervention":3871,"totalTrials":180,"cells":3872},"blood draw",{"EARLY_PHASE1":3873,"PHASE1":3875,"PHASE2":3877,"PHASE3":3879,"PHASE4":3881,"NA":3883},{"trials":3874,"activeCount":99},[],{"trials":3876,"activeCount":99},[],{"trials":3878,"activeCount":99},[],{"trials":3880,"activeCount":99},[],{"trials":3882,"activeCount":99},[],{"trials":3884,"activeCount":99},[3885,3891],{"nctId":3886,"briefTitle":3887,"status":258,"phases":3888,"primaryCompletion":667,"completion":667,"start":2660,"enrollment":3355,"conditions":3889,"interventions":3890},"NCT00855556","Parkinson's Disease Genetics Database",[],[1283],[3871],{"nctId":3892,"briefTitle":3893,"status":208,"phases":3894,"primaryCompletion":1351,"start":3895,"enrollment":99,"conditions":3896,"interventions":3901},"NCT00883805","Investigation of Systemic Metal Ion Concentration Following a Ceramic-on-metal Total Hip Arthroplasty",[],"2009-04",[3897,3898,3899,3900],"Hip Replacement","Hip Implant","Total Hip Arthroplasty","Orthopaedic Surgery",[3902],"Blood draw",{"intervention":3904,"totalTrials":313,"cells":3905},"Campath",{"EARLY_PHASE1":3906,"PHASE1":3908,"PHASE2":3910,"PHASE3":3912,"PHASE4":3914,"NA":3916},{"trials":3907,"activeCount":99},[],{"trials":3909,"activeCount":99},[],{"trials":3911,"activeCount":99},[],{"trials":3913,"activeCount":99},[],{"trials":3915,"activeCount":99},[],{"trials":3917,"activeCount":99},[3918],{"nctId":3919,"briefTitle":3920,"status":258,"phases":3921,"primaryCompletion":2110,"completion":2110,"start":3922,"enrollment":1617,"conditions":3923,"interventions":3925},"NCT00587847","Campath Maintenance in Chronic Lymphocytic Leukemia",[91],"2005-08",[3924],"Chronic Lymphocytic Leukemia",[3904],{"intervention":3927,"totalTrials":313,"cells":3928},"Montelukast",{"EARLY_PHASE1":3929,"PHASE1":3931,"PHASE2":3933,"PHASE3":3935,"PHASE4":3937,"NA":3939},{"trials":3930,"activeCount":99},[],{"trials":3932,"activeCount":99},[],{"trials":3934,"activeCount":99},[],{"trials":3936,"activeCount":99},[],{"trials":3938,"activeCount":99},[],{"trials":3940,"activeCount":99},[3941],{"nctId":3942,"briefTitle":3943,"status":111,"phases":3944,"primaryCompletion":2062,"completion":2062,"start":1927,"enrollment":3945,"conditions":3946,"interventions":3948},"NCT01329939","The Effect of Montelukast on Asthma Control in Overweight\u002FObese Atopic Asthmatics",[91],26,[2173,1773,3947],"Inflammation",[3927,3927],{"intervention":3950,"totalTrials":313,"cells":3951},"Nitroglycerin 0.4 mg sublingual",{"EARLY_PHASE1":3952,"PHASE1":3954,"PHASE2":3956,"PHASE3":3958,"PHASE4":3960,"NA":3962},{"trials":3953,"activeCount":99},[],{"trials":3955,"activeCount":99},[],{"trials":3957,"activeCount":99},[],{"trials":3959,"activeCount":99},[],{"trials":3961,"activeCount":99},[],{"trials":3963,"activeCount":99},[3964],{"nctId":3965,"briefTitle":3966,"status":208,"phases":3967,"primaryCompletion":3968,"completion":3968,"start":3969,"enrollment":99,"conditions":3970,"interventions":3971},"NCT01104597","Study to Evaluate Subclinical Atherosclerosis (an Early Sign of Heart Disease) in Healthy Adult Immigrant Asian Indians",[91],"2012-12","2010-04",[1772],[3950],{"intervention":3973,"totalTrials":313,"cells":3974},"Gallium-68 DOTATOC",{"EARLY_PHASE1":3975,"PHASE1":3977,"PHASE2":3979,"PHASE3":3981,"PHASE4":3983,"NA":3985},{"trials":3976,"activeCount":99},[],{"trials":3978,"activeCount":99},[],{"trials":3980,"activeCount":99},[],{"trials":3982,"activeCount":99},[],{"trials":3984,"activeCount":99},[],{"trials":3986,"activeCount":99},[3987],{"nctId":3988,"briefTitle":3989,"status":3990,"phases":3991,"primaryCompletion":1470,"completion":2539,"start":3162,"conditions":3992,"interventions":3994},"NCT02375464","Gallium-68 DOTATOC for Management of Neuroendocrine Tumors","NO_LONGER_AVAILABLE",[],[3993],"Neuroendocrine Tumors",[3973],{"intervention":3996,"totalTrials":313,"cells":3997},"In Vitro maturation",{"EARLY_PHASE1":3998,"PHASE1":4000,"PHASE2":4002,"PHASE3":4004,"PHASE4":4006,"NA":4008},{"trials":3999,"activeCount":99},[],{"trials":4001,"activeCount":99},[],{"trials":4003,"activeCount":99},[],{"trials":4005,"activeCount":99},[],{"trials":4007,"activeCount":99},[],{"trials":4009,"activeCount":99},[4010],{"nctId":4011,"briefTitle":4012,"status":208,"phases":4013,"primaryCompletion":2539,"completion":4014,"start":331,"enrollment":99,"conditions":4015,"interventions":4019},"NCT01843569","In Vitro Maturation (IVM) of Human Oocytes",[91],"2020-12",[4016,4017,4018],"Polycystic Ovarian Syndrome (PCOS)","Patients Sensitive to Exogenous Gonadotropins","Ovarian Hyper Stimulation Syndrome (OHSS)",[3996],{"intervention":4021,"totalTrials":313,"cells":4022},"Risperidone or Aripiprazole",{"EARLY_PHASE1":4023,"PHASE1":4025,"PHASE2":4027,"PHASE3":4029,"PHASE4":4031,"NA":4033},{"trials":4024,"activeCount":99},[],{"trials":4026,"activeCount":99},[],{"trials":4028,"activeCount":99},[],{"trials":4030,"activeCount":99},[],{"trials":4032,"activeCount":99},[],{"trials":4034,"activeCount":99},[4035],{"nctId":4036,"briefTitle":4037,"status":111,"phases":4038,"primaryCompletion":2788,"completion":2788,"start":220,"enrollment":4039,"conditions":4040,"interventions":4041},"NCT02822092","Striatal Connectivity and Clinical Outcome in Psychosis",[],196,[191],[4021],{"intervention":4043,"totalTrials":313,"cells":4044},"Chronotherapy",{"EARLY_PHASE1":4045,"PHASE1":4047,"PHASE2":4049,"PHASE3":4051,"PHASE4":4053,"NA":4055},{"trials":4046,"activeCount":99},[],{"trials":4048,"activeCount":99},[],{"trials":4050,"activeCount":99},[],{"trials":4052,"activeCount":99},[],{"trials":4054,"activeCount":99},[],{"trials":4056,"activeCount":99},[4057],{"nctId":4058,"briefTitle":4059,"status":208,"phases":4060,"primaryCompletion":2637,"start":3969,"enrollment":99,"conditions":4061,"interventions":4063},"NCT01120613","Post Kidney Transplant Nocturnal Hypertension Prevalence and Management Study",[91],[4062],"Hypertension",[4043],{"intervention":4065,"totalTrials":313,"cells":4066},"ziprasidone vs risperidone or olanzapine",{"EARLY_PHASE1":4067,"PHASE1":4069,"PHASE2":4071,"PHASE3":4073,"PHASE4":4075,"NA":4077},{"trials":4068,"activeCount":99},[],{"trials":4070,"activeCount":99},[],{"trials":4072,"activeCount":99},[],{"trials":4074,"activeCount":99},[],{"trials":4076,"activeCount":99},[],{"trials":4078,"activeCount":99},[4079],{"nctId":4080,"briefTitle":4081,"status":111,"phases":4082,"primaryCompletion":4083,"completion":4083,"start":4084,"enrollment":4085,"conditions":4086,"interventions":4087},"NCT00225498","Neurocognitive Effects of Ziprasidone: Relationship to Working Memory and Dopamine Blockade",[91],"2008-10","2002-06",35,[15],[4065],{"intervention":193,"totalTrials":313,"cells":4089},{"EARLY_PHASE1":4090,"PHASE1":4092,"PHASE2":4094,"PHASE3":4096,"PHASE4":4098,"NA":4100},{"trials":4091,"activeCount":99},[],{"trials":4093,"activeCount":99},[],{"trials":4095,"activeCount":99},[],{"trials":4097,"activeCount":99},[],{"trials":4099,"activeCount":99},[],{"trials":4101,"activeCount":99},[4102],{"nctId":184,"briefTitle":185,"status":111,"phases":4103,"completion":187,"start":188,"enrollment":29,"conditions":4104,"interventions":4105},[91],[190,191],[167,193],{"intervention":4107,"totalTrials":313,"cells":4108},"Oxygen",{"EARLY_PHASE1":4109,"PHASE1":4111,"PHASE2":4113,"PHASE3":4115,"PHASE4":4117,"NA":4119},{"trials":4110,"activeCount":99},[],{"trials":4112,"activeCount":99},[],{"trials":4114,"activeCount":99},[],{"trials":4116,"activeCount":99},[],{"trials":4118,"activeCount":99},[],{"trials":4120,"activeCount":99},[4121],{"nctId":4122,"briefTitle":4123,"status":258,"phases":4124,"primaryCompletion":2936,"completion":2936,"start":1928,"enrollment":1320,"conditions":4125,"interventions":4127},"NCT00547456","Consequences of Nocturnal and Daytime Hypoxemia in COPD",[91],[4126],"Chronic Obstructive Pulmonary Disease",[4107],{"intervention":4129,"totalTrials":313,"cells":4130},"Ranolazine",{"EARLY_PHASE1":4131,"PHASE1":4133,"PHASE2":4135,"PHASE3":4137,"PHASE4":4139,"NA":4141},{"trials":4132,"activeCount":99},[],{"trials":4134,"activeCount":99},[],{"trials":4136,"activeCount":99},[],{"trials":4138,"activeCount":99},[],{"trials":4140,"activeCount":99},[],{"trials":4142,"activeCount":99},[4143],{"nctId":4144,"briefTitle":4145,"status":258,"phases":4146,"primaryCompletion":3685,"completion":3685,"start":4147,"enrollment":677,"conditions":4148,"interventions":4154},"NCT01590979","Randomized Double Blind Control Trial on Effects of Ranolazine on New Onset Atrial Fibrillation",[91],"2012-04",[4149,4150,4151,4152,4153],"Atrial Fibrillation New Onset","Hemorrhage","Prolonged QTc Interval","Ventricular Tachycardia","Medical Care; Complications, Late Effect of Complications",[4129],{"intervention":4156,"totalTrials":313,"cells":4157},"Skin antisepsis with chlorhexidine",{"EARLY_PHASE1":4158,"PHASE1":4160,"PHASE2":4162,"PHASE3":4164,"PHASE4":4166,"NA":4168},{"trials":4159,"activeCount":99},[],{"trials":4161,"activeCount":99},[],{"trials":4163,"activeCount":99},[],{"trials":4165,"activeCount":99},[],{"trials":4167,"activeCount":99},[],{"trials":4169,"activeCount":99},[4170],{"nctId":4171,"briefTitle":4172,"status":208,"phases":4173,"primaryCompletion":331,"completion":3685,"start":261,"enrollment":99,"conditions":4174,"interventions":4176},"NCT00896402","Chlorhexidine Versus Betadine in Preventing Colonization of Femoral Nerve Catheters After Total Joint Arthroplasty (TJA)",[91],[4175],"Infection",[4156,4177],"povidone-iodine",{"intervention":4177,"totalTrials":313,"cells":4179},{"EARLY_PHASE1":4180,"PHASE1":4182,"PHASE2":4184,"PHASE3":4186,"PHASE4":4188,"NA":4190},{"trials":4181,"activeCount":99},[],{"trials":4183,"activeCount":99},[],{"trials":4185,"activeCount":99},[],{"trials":4187,"activeCount":99},[],{"trials":4189,"activeCount":99},[],{"trials":4191,"activeCount":99},[4192],{"nctId":4171,"briefTitle":4172,"status":208,"phases":4193,"primaryCompletion":331,"completion":3685,"start":261,"enrollment":99,"conditions":4194,"interventions":4195},[91],[4175],[4156,4177],{"intervention":4197,"totalTrials":313,"cells":4198},"doxycycline",{"EARLY_PHASE1":4199,"PHASE1":4201,"PHASE2":4203,"PHASE3":4205,"PHASE4":4207,"NA":4209},{"trials":4200,"activeCount":99},[],{"trials":4202,"activeCount":99},[],{"trials":4204,"activeCount":99},[],{"trials":4206,"activeCount":99},[],{"trials":4208,"activeCount":99},[],{"trials":4210,"activeCount":99},[4211],{"nctId":4212,"briefTitle":4213,"status":208,"phases":4214,"primaryCompletion":4215,"completion":4215,"start":4216,"enrollment":99,"conditions":4217,"interventions":4219},"NCT01188954","Doxycycline Versus Standard Care to Prevent Seroma Formation",[91],"2012-11","2010-01",[4218],"Seroma",[4197],{"intervention":4221,"totalTrials":313,"cells":4222},"blood draw, breathing test",{"EARLY_PHASE1":4223,"PHASE1":4225,"PHASE2":4227,"PHASE3":4229,"PHASE4":4231,"NA":4233},{"trials":4224,"activeCount":99},[],{"trials":4226,"activeCount":99},[],{"trials":4228,"activeCount":99},[],{"trials":4230,"activeCount":99},[],{"trials":4232,"activeCount":99},[],{"trials":4234,"activeCount":99},[4235],{"nctId":4236,"briefTitle":4237,"status":111,"phases":4238,"primaryCompletion":150,"completion":150,"start":4239,"enrollment":4240,"conditions":4241,"interventions":4242},"NCT02574351","Study of T-Regulatory Cells in Asthma",[],"2011-05",66,[2173],[4221],{"intervention":4244,"totalTrials":313,"cells":4245},"Vitamin B12",{"EARLY_PHASE1":4246,"PHASE1":4248,"PHASE2":4250,"PHASE3":4252,"PHASE4":4254,"NA":4256},{"trials":4247,"activeCount":99},[],{"trials":4249,"activeCount":99},[],{"trials":4251,"activeCount":99},[],{"trials":4253,"activeCount":99},[],{"trials":4255,"activeCount":99},[],{"trials":4257,"activeCount":99},[4258],{"nctId":4259,"briefTitle":4260,"status":111,"phases":4261,"primaryCompletion":1927,"completion":1927,"start":4262,"enrollment":4263,"conditions":4264,"interventions":4266},"NCT01876732","Impact of Vitamin B12 Replacement on Epogen Dosing and Improvement of Quality of Life in Hemodialysis Patients",[91],"2009-06",132,[4265],"Vitamin B12 Deficiency",[4244],{"intervention":4268,"totalTrials":313,"cells":4269},"PGx testing guided treatment",{"EARLY_PHASE1":4270,"PHASE1":4272,"PHASE2":4274,"PHASE3":4276,"PHASE4":4278,"NA":4280},{"trials":4271,"activeCount":99},[],{"trials":4273,"activeCount":99},[],{"trials":4275,"activeCount":99},[],{"trials":4277,"activeCount":99},[],{"trials":4279,"activeCount":99},[],{"trials":4281,"activeCount":99},[4282],{"nctId":4283,"briefTitle":4284,"status":111,"phases":4285,"primaryCompletion":4286,"completion":4286,"start":4287,"enrollment":742,"conditions":4288,"interventions":4289},"NCT02566057","Prospective Pharmacogenetic Testing and Clinical Outcomes in Patients With Early-Phase Psychosis",[91],"2017-12-31","2014-07-10",[15,28,1668,191,24],[4268],{"intervention":4291,"totalTrials":313,"cells":4292},"OnabotulinumtoxinA Standard Dose",{"EARLY_PHASE1":4293,"PHASE1":4295,"PHASE2":4297,"PHASE3":4299,"PHASE4":4301,"NA":4303},{"trials":4294,"activeCount":99},[],{"trials":4296,"activeCount":99},[],{"trials":4298,"activeCount":99},[],{"trials":4300,"activeCount":99},[],{"trials":4302,"activeCount":99},[],{"trials":4304,"activeCount":99},[4305],{"nctId":4306,"briefTitle":4307,"status":208,"phases":4308,"primaryCompletion":4309,"completion":4310,"start":4311,"enrollment":99,"conditions":4312,"interventions":4314},"NCT04994990","Effective OnabotulinumtoxinA Dose Response Study for Upper Facial Wrinkles",[91],"2024-11-30","2025-05-30","2023-05-25",[4313],"Rhytides",[4291,4315],"OnabotulinumtoxinA Half Standard Dose",{"intervention":4315,"totalTrials":313,"cells":4317},{"EARLY_PHASE1":4318,"PHASE1":4320,"PHASE2":4322,"PHASE3":4324,"PHASE4":4326,"NA":4328},{"trials":4319,"activeCount":99},[],{"trials":4321,"activeCount":99},[],{"trials":4323,"activeCount":99},[],{"trials":4325,"activeCount":99},[],{"trials":4327,"activeCount":99},[],{"trials":4329,"activeCount":99},[4330],{"nctId":4306,"briefTitle":4307,"status":208,"phases":4331,"primaryCompletion":4309,"completion":4310,"start":4311,"enrollment":99,"conditions":4332,"interventions":4333},[91],[4313],[4291,4315],{"intervention":4335,"totalTrials":313,"cells":4336},"nusinersen",{"EARLY_PHASE1":4337,"PHASE1":4339,"PHASE2":4341,"PHASE3":4343,"PHASE4":4345,"NA":4347},{"trials":4338,"activeCount":99},[],{"trials":4340,"activeCount":99},[],{"trials":4342,"activeCount":99},[],{"trials":4344,"activeCount":99},[],{"trials":4346,"activeCount":99},[],{"trials":4348,"activeCount":99},[4349],{"nctId":4350,"briefTitle":4351,"status":111,"phases":4352,"primaryCompletion":4353,"completion":4353,"start":4354,"enrollment":1617,"conditions":4355,"interventions":4357},"NCT03878030","Effect of Nusinersen on Adults With Spinal Muscular Atrophy",[],"2021-07-13","2019-04-01",[4356],"Adult Spinal Muscular Atrophy",[4335],{"intervention":4359,"totalTrials":313,"cells":4360},"131-I-meta-iodobenzylguanidine",{"EARLY_PHASE1":4361,"PHASE1":4363,"PHASE2":4365,"PHASE3":4367,"PHASE4":4369,"NA":4371},{"trials":4362,"activeCount":99},[],{"trials":4364,"activeCount":99},[],{"trials":4366,"activeCount":99},[],{"trials":4368,"activeCount":99},[],{"trials":4370,"activeCount":99},[],{"trials":4372,"activeCount":99},[4373],{"nctId":4374,"briefTitle":4375,"status":4376,"phases":4377,"conditions":4378,"interventions":4381},"NCT03015844","A Compassionate Use\u002FExpanded Access Protocol Using 131I-MIBG Therapy for Patients With Refractory Neuroblastoma and Metastatic Pheochromocytoma","AVAILABLE",[],[4379,4380],"Neuroblastoma","Pheochromocytoma",[4359],{"intervention":4383,"totalTrials":313,"cells":4384},"Rituximab",{"EARLY_PHASE1":4385,"PHASE1":4387,"PHASE2":4389,"PHASE3":4391,"PHASE4":4393,"NA":4395},{"trials":4386,"activeCount":99},[],{"trials":4388,"activeCount":99},[],{"trials":4390,"activeCount":99},[],{"trials":4392,"activeCount":99},[],{"trials":4394,"activeCount":99},[],{"trials":4396,"activeCount":99},[4397],{"nctId":4398,"briefTitle":4399,"status":208,"phases":4400,"primaryCompletion":2110,"completion":2110,"start":2540,"enrollment":99,"conditions":4401,"interventions":4403},"NCT00908986","Open Label Pilot Trial of Rituximab in Lupus Membranous Nephritis",[91],[4402],"Lupus Nephritis",[4383],{"intervention":4405,"totalTrials":313,"cells":4406},"Pravastatin, Fenofibrate, Metformin, Orlistat, irbesartan",{"EARLY_PHASE1":4407,"PHASE1":4409,"PHASE2":4411,"PHASE3":4413,"PHASE4":4415,"NA":4417},{"trials":4408,"activeCount":99},[],{"trials":4410,"activeCount":99},[],{"trials":4412,"activeCount":99},[],{"trials":4414,"activeCount":99},[],{"trials":4416,"activeCount":99},[],{"trials":4418,"activeCount":99},[4419],{"nctId":4420,"briefTitle":4421,"status":258,"phases":4422,"primaryCompletion":4423,"completion":4423,"start":4424,"enrollment":29,"conditions":4425,"interventions":4427},"NCT00794963","Aggressive Treatment of Metabolic Syndrome in Patients Receiving Clozapine for Schizophrenia",[91],"2010-05","2008-11",[4426],"Metabolic Syndrome",[4405],{"intervention":4429,"totalTrials":313,"cells":4430},"Omegaven IV",{"EARLY_PHASE1":4431,"PHASE1":4433,"PHASE2":4435,"PHASE3":4437,"PHASE4":4439,"NA":4441},{"trials":4432,"activeCount":99},[],{"trials":4434,"activeCount":99},[],{"trials":4436,"activeCount":99},[],{"trials":4438,"activeCount":99},[],{"trials":4440,"activeCount":99},[],{"trials":4442,"activeCount":99},[4443],{"nctId":4444,"briefTitle":4445,"status":3990,"phases":4446,"conditions":4447,"interventions":4450},"NCT02477345","Compassionate Use of Omegaven IV Fat Emulsion",[],[4448,4449],"Cholestasis","Liver Disease",[4429],{"intervention":4452,"totalTrials":313,"cells":4453},"Antibody testing",{"EARLY_PHASE1":4454,"PHASE1":4456,"PHASE2":4458,"PHASE3":4460,"PHASE4":4462,"NA":4464},{"trials":4455,"activeCount":99},[],{"trials":4457,"activeCount":99},[],{"trials":4459,"activeCount":99},[],{"trials":4461,"activeCount":99},[],{"trials":4463,"activeCount":99},[],{"trials":4465,"activeCount":99},[4466],{"nctId":4467,"briefTitle":4468,"status":111,"phases":4469,"primaryCompletion":4470,"completion":4471,"start":4472,"enrollment":4473,"conditions":4474,"interventions":4475},"NCT04542200","Workforce Serosurveillance to Track Long-term Modifications to COVID-19 Exposure Due to Factors in the Built Environment",[],"2022-07-31","2022-12-31","2021-01-01",40132,[2371],[4452],{"intervention":4477,"totalTrials":313,"cells":4478},"imipramine",{"EARLY_PHASE1":4479,"PHASE1":4481,"PHASE2":4483,"PHASE3":4485,"PHASE4":4487,"NA":4489},{"trials":4480,"activeCount":99},[],{"trials":4482,"activeCount":99},[],{"trials":4484,"activeCount":99},[],{"trials":4486,"activeCount":99},[],{"trials":4488,"activeCount":99},[],{"trials":4490,"activeCount":99},[4491],{"nctId":4492,"briefTitle":4493,"status":111,"phases":4494,"primaryCompletion":4495,"completion":4495,"start":4496,"enrollment":4497,"conditions":4498,"interventions":4500},"NCT00004834","Randomized Study of Cognitive-Behavioral Therapy vs Imipramine and Their Combination for Panic Disorder",[91],"2005-06","1998-05",326,[4499],"Panic Disorder",[4477],{"intervention":4502,"totalTrials":313,"cells":4503},"aprepitant 40 mg",{"EARLY_PHASE1":4504,"PHASE1":4506,"PHASE2":4508,"PHASE3":4510,"PHASE4":4512,"NA":4514},{"trials":4505,"activeCount":99},[],{"trials":4507,"activeCount":99},[],{"trials":4509,"activeCount":99},[],{"trials":4511,"activeCount":99},[],{"trials":4513,"activeCount":99},[],{"trials":4515,"activeCount":99},[4516],{"nctId":4517,"briefTitle":4518,"status":208,"phases":4519,"primaryCompletion":4520,"completion":4520,"start":4521,"enrollment":99,"conditions":4522,"interventions":4524},"NCT00699894","Aprepitant PO vs Ondansetron IV for Prevention of Postoperative Nausea and Vomiting",[91],"2008-09","2008-06",[4523],"Postoperative Nausea and Vomiting",[4502,4525],"ondansetron 4 mg",{"intervention":4525,"totalTrials":313,"cells":4527},{"EARLY_PHASE1":4528,"PHASE1":4530,"PHASE2":4532,"PHASE3":4534,"PHASE4":4536,"NA":4538},{"trials":4529,"activeCount":99},[],{"trials":4531,"activeCount":99},[],{"trials":4533,"activeCount":99},[],{"trials":4535,"activeCount":99},[],{"trials":4537,"activeCount":99},[],{"trials":4539,"activeCount":99},[4540],{"nctId":4517,"briefTitle":4518,"status":208,"phases":4541,"primaryCompletion":4520,"completion":4520,"start":4521,"enrollment":99,"conditions":4542,"interventions":4543},[91],[4523],[4502,4525]]